[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 20961
1. Díez L, Guijarro IG, Vaamonde P, Fernández P: [Primary manifestation of Hodgkin lymphoma in adenoid. About a case]. Acta Otorrinolaringol Esp; 2010 Nov-Dec;61(6):462-4
MedlinePlus Health Information. consumer health - Tonsils and Adenoids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary manifestation of Hodgkin lymphoma in adenoid. About a case].
  • [Transliterated title] Manifestación primaria de linfoma de Hodgkin en adenoides. A propósito de un caso.
  • Lymphomas are the second leading cause of malignancy in head and neck.
  • Hodgkin's disease (HD) accounts for only 10-35% of all cases, where the lymph node is affected in 70-80%.
  • We present the case of a patient with HD with extranodal involvement, given the rarity of this entity.
  • [MeSH-major] Adenoids. Hodgkin Disease / diagnosis. Pharyngeal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 Elsevier España, S.L. All rights reserved.
  • (PMID = 20092806.001).
  • [ISSN] 1988-3013
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


2. Liu TY, Wu SJ, Huang MH, Lo FY, Tsai MH, Tsai CH, Hsu SM, Lin CW: EBV-positive Hodgkin lymphoma is associated with suppression of p21cip1/waf1 and a worse prognosis. Mol Cancer; 2010;9:32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EBV-positive Hodgkin lymphoma is associated with suppression of p21cip1/waf1 and a worse prognosis.
  • BACKGROUND: About 30-50% of Hodgkin lymphomas (HLs) harbor the Epstein-Barr virus (EBV), but the impact of EBV infection on clinical outcomes has been unclear.
  • RESULTS: EBER1 was transfected into two HL cell lines, KMH2 and L428, and microarrays were used to screen for EBER1-induced changes.
  • We found that EBER1 suppressed p21cip1/waf1 transcription in HL cell lines.
  • Suppression of p21cip1/waf1 in the EBER1+ HL cell lines was associated with increased resistance to histone deacetylase inhibitors or proteasome inhibitors, drugs known to cause apoptosis by increasing p21cip1/waf1 levels.
  • On biopsy specimens, EBV+ HLs had weaker expression of both p21cip1/waf1 and active caspase 3.
  • Clinically, suppression of p21cip1/waf1 in EBV+ HLs was associated with a worse 2-year disease-free survival rate (45% for EBV+ HLs vs. 77% for EBV- HLs, p = 0.002).
  • The anti-apoptotic activity of EBER1 may be important in the rescue of Reed-Sternberg cells from drug-induced apoptosis and in the clinical behaviors of EBV+ HLs.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Herpesvirus 4, Human / physiology. Hodgkin Disease / diagnosis. Hodgkin Disease / virology
  • [MeSH-minor] Apoptosis / drug effects. Cell Cycle / drug effects. Cell Line, Tumor. Cyclin D2 / metabolism. Drug Resistance, Neoplasm / drug effects. Early Growth Response Protein 1 / genetics. Early Growth Response Protein 1 / metabolism. Gene Expression Regulation, Neoplastic / drug effects. Humans. Hydroxamic Acids / pharmacology. Leupeptins / pharmacology. Models, Biological. Prognosis. RNA, Viral / metabolism. STAT1 Transcription Factor / genetics. STAT1 Transcription Factor / metabolism. Transcription, Genetic / drug effects. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 2000 Dec 15;19(24):6742-50 [11118209.001]
  • [Cites] J Clin Oncol. 2009 Aug 10;27(23):3815-21 [19470931.001]
  • [Cites] EMBO J. 2002 Mar 1;21(5):954-65 [11867523.001]
  • [Cites] Blood. 2002 Jul 1;100(1):36-42 [12070005.001]
  • [Cites] Bioinformatics. 2002 Nov;18(11):1540-1 [12424128.001]
  • [Cites] Mol Cancer Ther. 2002 Jun;1(8):639-49 [12479224.001]
  • [Cites] Mol Pathol. 2000 Oct;53(5):238-47 [11091847.001]
  • [Cites] J Virol. 2003 Jan;77(2):1481-500 [12502863.001]
  • [Cites] Cell. 2003 Oct 3;115(1):71-82 [14532004.001]
  • [Cites] Oncogene. 2003 Oct 16;22(46):7181-91 [14562046.001]
  • [Cites] Eur J Biochem. 2004 May;271(10):1895-905 [15128299.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5332-7 [15289339.001]
  • [Cites] J Virol. 2004 Nov;78(21):11487-505 [15479791.001]
  • [Cites] Leukemia. 1988 Jun;2(6):371-6 [3131596.001]
  • [Cites] Cancer Res. 1994 Mar 1;54(5):1169-74 [8118801.001]
  • [Cites] Science. 1996 May 3;272(5262):719-22 [8614832.001]
  • [Cites] EMBO J. 1996 Jun 3;15(11):2748-59 [8654372.001]
  • [Cites] Annu Rev Med. 1999;50:401-23 [10073286.001]
  • [Cites] Pathol Int. 1999 Jun;49(6):506-12 [10469393.001]
  • [Cites] J Cell Biochem. 2005 Jan 1;94(1):153-67 [15523672.001]
  • [Cites] Rev Med Virol. 2005 Jan-Feb;15(1):3-15 [15386591.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):3980-5 [15899785.001]
  • [Cites] Curr Opin Cell Biol. 2005 Jun;17(3):302-8 [15901501.001]
  • [Cites] Nat Rev Microbiol. 2005 Oct;3(10):799-808 [16175175.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7604-13 [16186595.001]
  • [Cites] J Virol. 2005 Dec;79(23):14562-9 [16282456.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4339-44 [16076866.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1731-2 [16461762.001]
  • [Cites] Oncogene. 2006 Mar 16;25(12):1812-5 [16261158.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14935-40 [17001014.001]
  • [Cites] Leuk Lymphoma. 2006 Sep;47(9):1932-40 [17065008.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17337-42 [17085592.001]
  • [Cites] Drug Resist Updat. 2007 Feb-Apr;10(1-2):13-29 [17303468.001]
  • [Cites] Nucleic Acids Res. 2007;35(8):2503-12 [17395637.001]
  • [Cites] Clin Cancer Res. 2007 Jun 1;13(11):3380-7 [17545546.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(7-8):1367-74 [17412634.001]
  • [Cites] Mol Cell. 2007 Sep 21;27(6):890-900 [17889663.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3715-21 [17682125.001]
  • [Cites] Annu Rev Pathol. 2006;1:375-404 [18039120.001]
  • [Cites] Blood. 2008 Jan 1;111(1):292-301 [17720884.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1448-55 [18006702.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1369-77 [18316600.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 May;9(5):402-12 [18431400.001]
  • [Cites] J Cell Physiol. 2008 Aug;216(2):321-6 [18484093.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1424-33 [18541724.001]
  • [Cites] Oncogene. 2002 Feb 14;21(8):1285-94 [11850848.001]
  • (PMID = 20144199.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclin D2; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / EGR1 protein, human; 0 / Early Growth Response Protein 1; 0 / Epstein-Barr virus encoded RNA 1; 0 / Hydroxamic Acids; 0 / Leupeptins; 0 / RNA, Viral; 0 / STAT1 Transcription Factor; 0 / STAT1 protein, human; 0 / Tumor Suppressor Protein p53; 0 / carbobenzoxy-leucyl-leucyl-norvalinal; 3X2S926L3Z / trichostatin A
  • [Other-IDs] NLM/ PMC2834611
  •  go-up   go-down


3. Cyriac S, Sagar TG, Rajendranath R, Rathnam K: Hypereosinophilia in hodgkin lymphoma. Indian J Hematol Blood Transfus; 2008 Jun;24(2):67-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypereosinophilia in hodgkin lymphoma.
  • The incidence of eosinophilia in Hodgkin lymphoma is approximately 15%.
  • Both peripheral and tissue eosinophilia have been noted in Hodgkin lymphoma.
  • Eosinophils have important role in pathobiology of Hodgkin lymphoma.
  • We present a case who was diagnosed to have Hodgkin lymphoma and hypereosinophilia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1992 Mar 1;69(5):1248-53 [1739923.001]
  • [Cites] Ann Oncol. 1997;8 Suppl 2:89-96 [9209649.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1207-13 [10666192.001]
  • (PMID = 23100947.001).
  • [ISSN] 0971-4502
  • [Journal-full-title] Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
  • [ISO-abbreviation] Indian J Hematol Blood Transfus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3453044
  • [Keywords] NOTNLM ; Hodgkin lymphoma / Hypereosinophilia
  •  go-up   go-down


Advertisement
4. Gerstner ER, Abrey LE, Schiff D, Ferreri AJ, Lister A, Montoto S, Tsang R, Thiel E, Graus F, Behringer D, Illerhaus G, Weaver S, Wen P, Voloschin A, Harris NL, Batchelor TT: CNS Hodgkin lymphoma. Blood; 2008 Sep 1;112(5):1658-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS Hodgkin lymphoma.
  • Central nervous system (CNS) involvement by Hodgkin lymphoma (HL) is rare.
  • Detailed information was collected on 16 patients, the largest number to date, with meningeal or parenchymal CNS-HL confirmed by histopathology (15) or CSF (1).
  • Eight patients presented with CNS-HL at diagnosis, 2 of whom had isolated CNS disease, while 8 patients developed CNS-HL at relapse.
  • Median overall survival for all 16 patients was 60.9 months from first diagnosis of HL (systemic or CNS) and 43.8 months from diagnosis of CNS-HL.
  • Although a majority of patients have died, long-term survival is possible in patients who achieve a complete response to treatment, particularly those who present with CNS involvement or involvement of the CNS is the sole site of relapsed disease.
  • [MeSH-major] Central Nervous System Neoplasms / therapy. Hodgkin Disease / therapy
  • [MeSH-minor] Adult. Aged. Brain Neoplasms / diagnosis. Brain Neoplasms / pathology. Brain Neoplasms / therapy. Female. Humans. Male. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / pathology. Meningeal Neoplasms / therapy. Middle Aged. Prognosis. Recurrence. Survival Rate

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Mar;82(5):1117-21 [10737396.001]
  • [Cites] Acta Neuropathol. 2000 Jun;99(6):709-14 [10867808.001]
  • [Cites] Radiat Med. 2000 May-Jun;18(3):205-8 [10972552.001]
  • [Cites] Brain Pathol. 2001 Jul;11(3):387-8; 393 [11414479.001]
  • [Cites] Leuk Lymphoma. 2004 Aug;45(8):1667-71 [15370222.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3182 [17634503.001]
  • [Cites] Cancer. 1979 Apr;43(4):1497-506 [376094.001]
  • [Cites] Cancer. 1983 Oct 1;52(7):1301-7 [6883291.001]
  • [Cites] Clin Lab Haematol. 1989;11(4):331-8 [2605874.001]
  • [Cites] J Clin Oncol. 2007 Apr 10;25(11):1437-8 [17416864.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4228-30 [15483035.001]
  • (PMID = 18591379.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R13 CA124293
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3710443
  •  go-up   go-down


5. Wilkes L: Starting out - respecting the wishes of a dying patient made all the difference. Nurs Stand; 2009 Mar 11;23(27):27

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Starting out - respecting the wishes of a dying patient made all the difference.
  • : While on acute placement on a haematology unit, I looked after a patient who had non-Hodgkin's lymphoma, lung cancer and a hole in his neck where a tracheostomy had been situated.
  • John had been on the unit for a while and would constantly tell me and other staff members that he wanted to go home.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27991330.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


6. Navarro A, Gaya A, Martinez A, Urbano-Ispizua A, Pons A, Balagué O, Gel B, Abrisqueta P, Lopez-Guillermo A, Artells R, Montserrat E, Monzo M: MicroRNA expression profiling in classic Hodgkin lymphoma. Blood; 2008 Mar 1;111(5):2825-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA expression profiling in classic Hodgkin lymphoma.
  • We analyzed miRNA expression in classic Hodgkin lymphoma (cHL) and the influence of Epstein-Barr virus (EBV) infection on the miRNA expression profiles.
  • The expression of 157 miRNAs in lymph nodes from 49 cHL patients and 10 reactive lymph nodes (RLNs) was analyzed by real-time polymerase chain reaction (PCR).
  • Hierarchic clustering revealed 3 well-defined groups: nodular sclerosis cHL, mixed cellularity cHL, and RLNs.
  • A distinctive signature of 25 miRNAs differentiated cHL from RLNs, and 36 miRNAs were differentially expressed in the nodular sclerosis and mixed cellularity subtypes.
  • These results were validated in a set of 30 cHLs and 5 RLNs, and in 3 cHL cell lines. miR-96, miR-128a, and miR-128b were selectively down-regulated in cHL with EBV.
  • Our findings suggest that miRNAs play an important role in the biology of cHL and may be useful in developing therapies targeting miRNAs.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Hodgkin Disease / genetics. MicroRNAs / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Female. Herpesvirus 4, Human / physiology. Humans. In Situ Hybridization. Lymph Nodes / pathology. Male. Middle Aged

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18089852.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  •  go-up   go-down


7. Massini G, Siemer D, Hohaus S: EBV in Hodgkin Lymphoma. Mediterr J Hematol Infect Dis; 2009;1(2):e2009013

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EBV in Hodgkin Lymphoma.
  • Up to 40% of Hodgkin lymphoma (HL) cases are associated with the Epstein-Barr virus (EBV).
  • Clonal viral genomes can be found in the HL tumor cells, the Hodgkin Reed-Sternberg cells (HRS).
  • The presence of EBV in HL is associated with several clinicopathological characteristics: It is more frequent in cases with mixed cellular histology, in males, in children and older adults, and in developing countries, while the young-adult onset HL of nodular sclerosis type in industrialized countries is typically EBV-negative.
  • Recent studies suggest a genetic predisposition to develop EBV-associated HL.
  • Circulating EBV-DNA may serve as a biomarker to monitor response to therapy, and eventually, EBV will become a target for therapeutic intervention also in HL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2005 Dec 15;106(13):4345-50 [16131568.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7604-13 [16186595.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):460-4 [16428487.001]
  • [Cites] Oncogene. 2007 Mar 8;26(11):1650-5 [16983344.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11668-76 [17178861.001]
  • [Cites] Leuk Lymphoma. 2006 Jul;47(7):1315-21 [16923562.001]
  • [Cites] Cancer Lett. 2008 Oct 18;270(1):66-76 [18539384.001]
  • [Cites] Int J Cancer. 2008 Oct 1;123(7):1499-507 [18646185.001]
  • [Cites] J Intern Med. 2008 Dec;264(6):537-48 [19017178.001]
  • [Cites] J Infect Dis. 1979 May;139(5):553-8 [220340.001]
  • [Cites] Nature. 1989 Dec 21-28;342(6252):929-31 [2594086.001]
  • [Cites] J Infect Dis. 1971 Mar;123(3):263-70 [4329526.001]
  • [Cites] J Infect Dis. 1973 Apr;127(4):471-3 [4348499.001]
  • [Cites] Wistar Inst Symp Monogr. 1965 Sep;4:69-82 [5884338.001]
  • [Cites] Arch Virol. 1998;143(4):803-13 [9638150.001]
  • [Cites] J Med Virol. 1999 Apr;57(4):383-9 [10089051.001]
  • [Cites] Oncogene. 1999 May 20;18(20):3063-70 [10340377.001]
  • [Cites] J Pathol. 1999 Feb;187(3):326-30 [10398087.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4249-52 [16123211.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1853-61 [16385563.001]
  • [Cites] Ann Hematol. 2006 Jul;85(7):463-8 [16534596.001]
  • [Cites] Herpes. 2006 May;13(1):12-6 [16732997.001]
  • [Cites] Curr Top Microbiol Immunol. 2006;310:61-80 [16909907.001]
  • [Cites] Ann Oncol. 2007 Aug;18(8):1376-81 [17496310.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5771-8 [17575144.001]
  • [Cites] J Virol. 2007 Sep;81(18):10092-100 [17626071.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3310-5 [17630352.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1293-304 [17707260.001]
  • [Cites] Haematologica. 2007 Nov;92(11):1470-4 [18024394.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1342-9 [18042690.001]
  • [Cites] J Immunol. 2007 Dec 15;179(12):8225-34 [18056366.001]
  • [Cites] Int J Cancer. 2008 Aug 1;123(3):716-9 [18470916.001]
  • [Cites] Virology. 1991 Apr;181(2):595-608 [1849678.001]
  • [Cites] Am J Pathol. 2008 Jul;173(1):195-204 [18502823.001]
  • [Cites] J Mol Diagn. 2008 Jul;10(4):279-92 [18556771.001]
  • [Cites] J Pathol. 2008 Sep;216(1):83-92 [18566961.001]
  • [Cites] Leuk Lymphoma. 2008 Sep;49(9):1769-77 [18661399.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14(21):6974-8 [18980992.001]
  • [Cites] Nat Rev Cancer. 2009 Jan;9(1):15-27 [19078975.001]
  • [Cites] Blood. 2009 Mar 19;113(12):2765-3775 [19096012.001]
  • [Cites] Blood. 2009 Jun 4;113(23):5920-6 [19188663.001]
  • [Cites] Leuk Res. 2009 Oct;33(10):1352-6 [19201467.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):976-86 [19223558.001]
  • [Cites] J Exp Med. 2009 May 11;206(5):981-9 [19380639.001]
  • [Cites] Annu Rev Pathol. 2009;4:151-74 [19400691.001]
  • [Cites] Semin Cancer Biol. 2009 Jun;19(3):158-64 [19429479.001]
  • [Cites] J Clin Oncol. 2009 Aug 10;27(23):3815-21 [19470931.001]
  • [Cites] Nature. 1996 Jun 27;381(6585):751-8 [8657279.001]
  • [Cites] J Exp Med. 1996 Oct 1;184(4):1495-505 [8879220.001]
  • [Cites] J Virol. 1997 Jul;71(7):4882-91 [9188550.001]
  • [Cites] Blood. 1997 Aug 15;90(4):1664-72 [9269787.001]
  • [Cites] J Pathol. 1997 Jul;182(3):299-306 [9349232.001]
  • [Cites] EMBO J. 1998 Mar 16;17(6):1700-9 [9501091.001]
  • [Cites] Blood. 1999 Nov 1;94(9):3129-34 [10556199.001]
  • [Cites] Oncogene. 1999 Nov 22;18(49):6959-64 [10602470.001]
  • [Cites] J Exp Med. 2000 Jan 17;191(2):395-402 [10637284.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1522-8 [10995808.001]
  • [Cites] Immunity. 2000 Oct;13(4):485-95 [11070167.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2080-4 [11280769.001]
  • [Cites] Cancer. 2001 Apr 15;91(8):1579-87 [11301409.001]
  • [Cites] Br J Cancer. 2001 May 4;84(9):1227-34 [11336475.001]
  • [Cites] Mol Cell Biol. 2001 Jun;21(12):3964-73 [11359904.001]
  • [Cites] Br J Haematol. 2000 Oct;111(1):239-46 [11091207.001]
  • [Cites] Curr Oncol Rep. 2000 Mar;2(2):199-204 [11122844.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1276-87 [11423259.001]
  • [Cites] Curr Opin Oncol. 2001 Sep;13(5):360-7 [11555713.001]
  • [Cites] Eur J Cancer. 2001 Oct;37(15):1853-7 [11576839.001]
  • [Cites] Int J Cancer. 2002 Sep 20;101(3):259-64 [12209977.001]
  • [Cites] Ann Oncol. 2003 Feb;14(2):282-90 [12562657.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2114-20 [12796376.001]
  • [Cites] Pathol Oncol Res. 2003;9(3):159-65 [14530808.001]
  • [Cites] Nat Rev Immunol. 2001 Oct;1(1):75-82 [11905817.001]
  • [Cites] Blood. 2002 Apr 15;99(8):3060-2 [11929801.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4283-97 [12036854.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 1:23-9 [12078898.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):10084-9 [12110730.001]
  • [Cites] J Exp Med. 2002 Sep 2;196(5):605-17 [12208876.001]
  • [Cites] Blood. 2003 Jan 15;101(2):681-9 [12393683.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1505-12 [12393731.001]
  • [Cites] Nat Med. 2003 Mar;9(3):307-14 [12592401.001]
  • [Cites] Int J Cancer. 1999 Aug 20;84(4):442-8 [10404101.001]
  • [Cites] J Virol. 2000 Nov;74(22):10468-79 [11044091.001]
  • [Cites] J Pathol. 2003 Nov;201(3):413-20 [14595753.001]
  • [Cites] J Clin Pathol. 2003 Nov;56(11):811-6 [14600123.001]
  • [Cites] Trends Mol Med. 2004 Jul;10(7):331-6 [15242681.001]
  • [Cites] J Pathol. 2005 May;206(1):68-75 [15751051.001]
  • [Cites] Br J Haematol. 2005 May;129(4):511-9 [15877733.001]
  • [Cites] Saudi Med J. 2005 Apr;26(4):571-5 [15900362.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4339-44 [16076866.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1807-14 [11696441.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1474-7 [11830502.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4730-5 [12665622.001]
  • [Cites] Blood. 2003 Dec 1;102(12):4166-78 [12907455.001]
  • [Cites] N Engl J Med. 2003 Oct 2;349(14):1324-32 [14523140.001]
  • [Cites] Nat Rev Immunol. 2003 Oct;3(10):801-12 [14523386.001]
  • [Cites] Clin Immunol. 2003 Oct;109(1):53-63 [14585276.001]
  • [Cites] Int J Cancer. 2007 Jul 15;121(2):442-7 [17390376.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1326-9 [17438085.001]
  • [Cites] J Virol. 1995 Jun;69(6):3752-8 [7745723.001]
  • [Cites] Cancer. 1995 Mar 15;75(6):1360-6 [7882287.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10962-6 [7971992.001]
  • [Cites] Int J Cancer. 1993 Sep 30;55(3):359-63 [8397160.001]
  • [Cites] Mod Pathol. 1995 Aug;8(6):675-9 [8532705.001]
  • [Cites] Arch Dis Child. 1996 Jan;74(1):27-31 [8660041.001]
  • [Cites] Immunity. 1996 Aug;5(2):173-9 [8769480.001]
  • [Cites] Int J Cancer. 1997 Apr 10;71(2):138-41 [9139832.001]
  • [Cites] J Clin Invest. 1997 Dec 15;100(12):2961-9 [9399941.001]
  • [Cites] Cell. 1979 Jul;17(3):661-71 [225039.001]
  • [Cites] N Engl J Med. 1989 Feb 23;320(8):502-6 [2536894.001]
  • [Cites] J Exp Med. 1988 Dec 1;168(6):2059-75 [2848918.001]
  • [Cites] Proc Natl Acad Sci U S A. 1968 Jan;59(1):94-101 [5242134.001]
  • [Cites] Science. 1967 Sep 1;157(3792):1064-5 [6036237.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2447-51 [7919364.001]
  • [Cites] J Virol. 1994 Nov;68(11):7374-85 [7933121.001]
  • [Cites] Blood. 1993 Jan 15;81(2):496-501 [8380728.001]
  • [Cites] Int J Cancer. 1996 Mar 15;65(6):781-4 [8631592.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):239-44 [14688409.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1373-81 [15007085.001]
  • [Cites] Blood. 2004 Jul 1;104(1):243-9 [15031209.001]
  • [Cites] Br J Haematol. 2004 May;125(3):267-81 [15086409.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6611-6 [15096587.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2138-46 [15933052.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2444-51 [15941916.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4048-56 [15961758.001]
  • [Cites] Lancet. 2005 Jun 25-Jul 1;365(9478):2216-24 [15978930.001]
  • [Cites] J Allergy Clin Immunol. 2005 Aug;116(2):251-61; quiz 262 [16083776.001]
  • (PMID = 21416003.001).
  • [ISSN] 2035-3006
  • [Journal-full-title] Mediterranean journal of hematology and infectious diseases
  • [ISO-abbreviation] Mediterr J Hematol Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3033177
  •  go-up   go-down


8. Sweetenham JW: Novel therapies for Hodgkin Lymphoma. Ther Adv Hematol; 2010 Feb;1(1):23-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel therapies for Hodgkin Lymphoma.
  • In recent years, improved understanding of the biology of Hodgkin Lymphoma (HL) has uncovered many potential targets for the treatment of this disease.
  • Clarification of the B-ceLL origin of the Hodgkin Reed Sternberg (HRS) cell and of the complex interactions between the HRS cell and the HL microenvironment have provided new insights into the pathophysiology of HL and identified extracellular and intracellular molecules which are essential for HRS survival.
  • New agents directed at these molecules are now in early phase clinical trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23556069.001).
  • [ISSN] 2040-6207
  • [Journal-full-title] Therapeutic advances in hematology
  • [ISO-abbreviation] Ther Adv Hematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3573386
  • [Keywords] NOTNLM ; Hodgkin Lymphoma / new agents / targeted therapy
  •  go-up   go-down


9. Chawla R, Venkatesh P, Garg SP, Mandal S, Tewari HK: Cytomegalovirus retinitis in a patient with non-Hodgkins lymphoma: A diagnostic dilemma. Eur J Ophthalmol; 2005 Jan - Feb 2005;15(1):153-157

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomegalovirus retinitis in a patient with non-Hodgkins lymphoma: A diagnostic dilemma.
  • PURPOSE: Patients with lymphoma can rarely develop cytomegalovirus (CMV) retinitis.
  • Clinically it is difficult to distinguish from intraocular lymphoma.
  • The authors report a rare case of bilateral CMV retinitis in a patient with non-Hodgkins lymphoma with high CD4+ counts.
  • RESULTS: CMV retinitis was clinically suspected due to the presence of large areas of retinal necrosis and hemorrhages in one eye and a demarcation line with white mottled retina in the other eye.
  • The diagnosis of CMV retinitis was confirmed by polymerase chain reaction performed on vitreous sample.
  • CONCLUSIONS: CMV retinitis can develop in cases of lymphoma despite high CD4+ counts.
  • An early diagnosis can be established by performing PCR on vitreous biopsy. (Eur J Ophthalmol 2005; 15: #-7).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28221421.001).
  • [ISSN] 1724-6016
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


10. Carbone A, Cabras A, Gloghini A: HIV-associated Hodgkins lymphoma. Antiapoptotic pathways and mechanisms for immune escape by tumor cells in the setting of improved immunity. Int J Biol Markers; 2007 Apr - Jun;22(2):161-163

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated Hodgkins lymphoma. Antiapoptotic pathways and mechanisms for immune escape by tumor cells in the setting of improved immunity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28207144.001).
  • [ISSN] 1724-6008
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


11. Berker N, Batman C, Ozdamar Y, Eranil S, Aslan O, Zilelioglu O: Long-term outcomes of heavy silicone oil tamponade for complicated retinal detachment. Eur J Ophthalmol; 2007 Sep-Oct;17(1):797-803

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To assess the long-term success rates and complications of heavy silicone oil tamponade (Oxane HD) in the management of complicated retinal detachment with proliferative vitreoretinopathy (PVR).
  • Vitreoretinal surgery with heavy silicone oil (Oxane HD) tamponade was performed in all patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28221523.001).
  • [ISSN] 1724-6016
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


12. Klekawka T, Balwierz W, Moryl-Bujakowska A, Stanuch H, Matysiak M, Rokicka-Milewska R, Sopyło B, Kołakowska-Mrozowska B, Krenke K, Chybicka A, Chaber R, Sońita-Jakimczyki D, Janik-Moszants A, Wachowiak J, Kaczmarek-Kanold M, Kowalczyk J, Odój T, Balcerska A, Adamkiewicz-Drozyińska E, Wysocki M, Koltan A, Krawczuk-Rybako M, Muszyńska-Rosłan K, Stolarska M: [Does the residual mediastinal mass have prognostic significance in children with Hodgkin's disease (HD)?]. Przegl Lek; 2006;63(1):21-4
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Does the residual mediastinal mass have prognostic significance in children with Hodgkin's disease (HD)?].
  • [Transliterated title] Czy obecność przetrwałej zmiany w sródpiersiu ma znaczenie prognostyczne w chorobie Hodgkina (HD) u dzieci?
  • Prognostic significance of residual mediastinal tumor mass in children treated for HD as well as the choice of the optimal management of these cases still remains unknown.
  • In years 1994-2001 in 10 PPLLSG participating centers 480 children (age 2-19.7 years) were treated for HD (stages I-IV).
  • [MeSH-major] Hodgkin Disease / pathology. Hodgkin Disease / therapy. Mediastinal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16892894.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Poland
  •  go-up   go-down


13. Viscasillas Pallás G, Cisa Lluís E, Cruellas Taischik F, Doménech Juan I, Dicenta Sousa M: [Presentation of a case of cervical actinomycosis versus Hodgkin lymphoma]. An Otorrinolaringol Ibero Am; 2005;32(1):23-8
MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Presentation of a case of cervical actinomycosis versus Hodgkin lymphoma].
  • [Transliterated title] Actinomicosis cervical versus linfoma de Hodgkin. A propósito de un caso.
  • The evolution and clinical, anatomopathologic radiologic characteristic, and its presentation bring us to suspect another type of more frequent pathology: the neoplastic, that make very difficult its diagnosis.
  • We present the case of a young patient affected by a cervical tumoration initially oriented as Hodgkin lymphoma that finally was diagnosed as cervical actinomycosis and treated with penicillin.
  • [MeSH-major] Actinomycosis / diagnosis. Actinomycosis / microbiology. Cervical Vertebrae / microbiology. Hodgkin Disease / diagnosis. Propionibacterium / isolation & purification
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Tomography, X-Ray Computed


14. Garza-Sánchez J, Hernández-Ramírez DA, Rocha-Ramírez JL, Rojas-Illanes M, Parrado-Montaño W, Cancino-López JA, Dorantes-Díaz DE, Jonguitud-Muro LA: [Non Hodgkin lymphoma of the sigmoid colon: case report]. Rev Gastroenterol Mex; 2009 Apr-Jun;74(2):127-31
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non Hodgkin lymphoma of the sigmoid colon: case report].
  • [Transliterated title] Linfoma no Hodgkin de sigmoides: reporte de un caso.
  • Non-Hodgkin lymphoma (NHL) occurs in extranodal location in approximately 20% of patients with limited stage, high-grade disease.
  • Largely related to the lack of specific signs and symptoms, patients frequently present advanced locoregional disease.
  • Systemic adjuvant chemotherapy and abdominal radiation were administered.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse. Sigmoid Neoplasms

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19666296.001).
  • [ISSN] 0375-0906
  • [Journal-full-title] Revista de gastroenterología de México
  • [ISO-abbreviation] Rev Gastroenterol Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


15. Schnitzer B: Hodgkin lymphoma. Hematol Oncol Clin North Am; 2009 Aug;23(4):747-68
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin lymphoma.
  • Hodgkin disease was first described more than 175 years ago.
  • Clinically and histomorphologically, the features of Hodgkin lymphoma are unusual for a lymphoma or for other malignancies.
  • The incidence of Hodgkin lymphoma is estimated to be 7400 new cases per year in the United States, resulting in an age-adjusted yearly rate of 2.7 per 100,000 per year.
  • There have been numerous classifications of non-Hodgkin lymphoma over the years, but the organizational schemes of Hodgkin lymphoma have been stable.
  • This article reviews the diagnosis of the various types of Hodgkin lymphoma classification, diagnosis and differential.
  • [MeSH-major] Hodgkin Disease / classification. Hodgkin Disease / diagnosis. Reed-Sternberg Cells / pathology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19577168.001).
  • [ISSN] 1558-1977
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 142
  •  go-up   go-down


16. Stathis A, Hotte S, Hirte H, Chen EX, Webster S, Iacobucci A, McGill S, Wang L, Espinoza-Delgado I, Siu LL: Phase I study of intravenous decitabine in combination with oral vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas (NHL). J Clin Oncol; 2009 May 20;27(15_suppl):3528

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of intravenous decitabine in combination with oral vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas (NHL).
  • The ideal dose scheduling of these drugs remains controversial.
  • This phase I study aims to determine the recommended phase II dose (RPTD) of the combination, their toxicity profile, pharmacokinetic (PK) interaction and preliminary clinical activity.
  • Dose escalation of D and V on the sequential schedule is described in Table.
  • RESULTS: To date, 27 pts have been entered into dose levels 1, -1, 1a, 1b, -1b, -2b of the sequential schedule.
  • Dose limiting toxicities (DLT) consisted mainly of myelosuppression, constitutional and gastrointestinal symptoms occurred in 7/27 (26%) of pts so far.
  • Disease stabilization for 4 or more cycles was observed in 7 out of 22 (31.8%) evaluable pts (two with breast and one each of thymus, colon, pancreatic, appendix and non-small cell lung cancers).
  • CONCLUSIONS: The sequential combination of D and V seems to be tolerable after some adjustments in the doses and duration of drug administration.
  • Prolonged disease stabilization has been observed in multiple tumor types.
  • Accrual is ongoing and RPTD will likely be dose level -1b or -2b. ( Supported by NCI Grant No. U01CA132123.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961316.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Hernandez-Ilizaliturri FJ, Khubchandani S, Olejniczak SH, Hoskin P, Czuczman MS: Strategies to overcoming rituximab-chemotherapy resistance by targeting the autophagy pathway using bortezomib in combination with the Bcl-2 inhibitor obatoclax in non-Hodgkin's lymphomas (NHL). J Clin Oncol; 2009 May 20;27(15_suppl):8543

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strategies to overcoming rituximab-chemotherapy resistance by targeting the autophagy pathway using bortezomib in combination with the Bcl-2 inhibitor obatoclax in non-Hodgkin's lymphomas (NHL).
  • Studies were conducted in rituximab sensitive (RSCL) and resistant cell lines (RRCL), as well as in malignant B-cells derived from patients with NHL (n = 20).
  • Cells were exposed in vitro to escalating doses of O with/without B.
  • To further study the mechanisms of O and/or B action, RSCL or RRCL were exposed to O or B with or without caspase inhibitors; viability was evaluated as above and apoptosis by flow cytometry and PARP cleavage.
  • O or B monotherapy induced time- and dose-dependent cell death of all cells tested.
  • In vitro exposure of RRCL, RSCL and lymphoma specimens to O and B resulted in significant synergistic activity.
  • The ability of O or B to induce PARP cleavage varied between patient samples and was not observed in RRCL.
  • Inhibition of caspase activity did not affect the ability of O or B to kill NHL cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960960.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Powell SF, Dudek AZ: Response to high-dose interleukin-2 (HD IL-2) therapy in patients with brain metastases from metastatic melanoma. J Clin Oncol; 2009 May 20;27(15_suppl):e20007

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to high-dose interleukin-2 (HD IL-2) therapy in patients with brain metastases from metastatic melanoma.
  • : e20007 Background: HD IL-2 has been shown to produce durable responses in patients with metastatic melanoma.
  • METHODS: A retrospective analysis was performed all adult patients with Stage IV melanoma treated with HD IL-2 from January 2000 to October 2008 at our institution.
  • HD IL-2 was given I.V. every eight hours as a bolus over 15 minutes at a dose of 600,000 IU/kg.
  • A maximum of 14 doses for each course was given.
  • RESULTS: A total of 15 patients with metastatic melanoma had been treated with HD IL-2 at our institution.
  • Complete response (CR) was seen in 6.67% (N=1), partial response (PR) in 6.67% (N=1), mixed response (MR) in 6.67% (N=1), and stable disease (SD) in 13.33% (N=2).
  • Average time to disease progression (TTDP) was 5.67 months in those with a PR or SD.
  • Two patients with brain metastases had subsequently complete resolution of the brain lesions after HD IL-2 therapy.
  • One of these patients has a CR and is disease free 34 months out from therapy.
  • The other had PR and is currently alive with disease, but has no recurrence of the brain lesion after over 19 months.
  • On average patients tolerated 10.5 HD IL-2 doses with the first course and 8.8 doses with the second course.
  • CONCLUSIONS: The CR rate of 6.67% and TTDP in those with SD or a PR are comparable to previously published studies.
  • HD IL-2 has typically been avoided in patients with brain metastases due to concern for neurologic complications from the capillary leak syndrome caused by treatment.
  • We propose further evaluation of this ineligibility for HD IL-2, since carefully selected patients with brain metastases may derive benefit from this treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962593.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Rineer J, Schreiber D, Wortham A, Olsheski M, Sroufe R, Sura S, Katsoulakis E, Han P, Choi K, Rotman M: Utilization of radiation therapy in early-stage Hodgkin disease and its impact on survival. J Clin Oncol; 2009 May 20;27(15_suppl):8511

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utilization of radiation therapy in early-stage Hodgkin disease and its impact on survival.
  • : 8511 Background: Despite numerous randomized trials confirming the benefit of consolidation radiation therapy (RT) in the management of early stage Hodgkin disease (HD), utilization of RT in this setting remains variable.
  • METHODS: The surveillance, epidemiology and end results (SEER) registry was used to identify patients aged 15-75 years diagnosed between 1990-2004 with early stage (stage I-IIA/B) HD, excluding nodular lymphocyte predominant HD.
  • The majority (71.3%) had nodular sclerosis (NS) type HD.
  • By clinical stage, 3399 (34.9%) were stage I, and 6330 (65.1%) were stage II.
  • RT was more likely to be employed during the early era of treatment, in younger patients, females, non-Blacks, and in NS, mixed cellularity and lymphocyte-rich HD.
  • CONCLUSIONS: In this large population-based series of early stage HD patients, the use of RT is associated with a significant OS and CSS benefit across all subgroups.
  • Current efforts in clinical trials have aimed at decreasing the utilization of RT among this patient population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960874.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Lotz J, Selle F, Fizazi K, Gravis G, Bui B, Delva R, Bay J, Baron A, Robain M, Biron P: A phase II trial of high-dose chemotherapy (HDCT) supported by haematopoietic stem cell transplantation (HSCT) in patients (pts) with disseminated germ-cell tumors (GCTs) failing chemotherapy and with adverse prognostic factors: The TAXIF II protocol. J Clin Oncol; 2009 May 20;27(15_suppl):5028

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of high-dose chemotherapy (HDCT) supported by haematopoietic stem cell transplantation (HSCT) in patients (pts) with disseminated germ-cell tumors (GCTs) failing chemotherapy and with adverse prognostic factors: The TAXIF II protocol.
  • : 5028 Background: HDCT using the etoposide-carboplatin ± ifosfamide regimen is able to circumvent resistance in GCT pts, even when used as third-line or later therapy (Lotz, Ann Onco.l 2005 / Einhorn, N Eng J Med. 2007).
  • Thiotepa (TTP) and P can be safely combined at HD with good efficacy.
  • METHODS: Non-resistant/refractory GCTs pts failing CT and with adverse prognostic factors were planned to receive 2 cycles combining (mg/m<sup>2</sup>) E (100) and P (250), given on day 1 and 14 supported by filgrastim (F), followed by 3 consecutive HDCTs [1 course combining a 3-d combination of P (360) + TTP (720), followed by 2 ICE regimens (IFM, 12 g/m<sup>2</sup>, CBDCA, AUC 20, VP16, 1,500 mg/m<sup>2</sup>), given on 5 days with HSCT and F].
  • Inclusion criterias were mainly: radiologically and/or biologically mesurable disease, seminomatous GCT in relapse after 2 lines of CT (BEP/VeIP), non-seminomatous GCT in relapse after 1 or 2 lines of CT or in PR after 1 line of CT, primary mediastinal GCT in first relapse.
  • RESULTS: From 09/04 to 12/07, 45 pre-treated (BEP ± VeIP) pts with gonadal (89%) or extra-gonadal T (11%) were treated in second-line (27%), 3rd-line (44 %) or more (29 %).
  • One pt died of multi-organ failure and 7 died of disease progression.
  • CONCLUSIONS: This HDCT program preceded by 2 semi-intensive cycles of E-P is highly effective in non-resistant/refractory pts with disseminated GCTS failing CT and with adverse prognostic factors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962914.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Delmer A, Fitoussi O, Gaulard P, Laurent G, Bordessoule D, Morschhauser F, Ferme C, Tilly H, Gisselbrecht C, Coiffier B, Groupe d'Etude des Lymphomes de l'Adulte (GELA): A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: Results of the GELA LNH05-1T trial. J Clin Oncol; 2009 May 20;27(15_suppl):8554

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: Results of the GELA LNH05-1T trial.
  • : 8554 Background: Patients with peripheral T/NK cell lymphomas (PTCL) still have a dismal prognosis with 5-yr survival less than 30% in most cases.
  • METHODS: Pts aged 18 to 65 yrs with previously untreated PTCL were planned to receive 4 bi-monthly cycles of ACVBP (doxorubicine 75 mg/m<sup>2</sup> D1, cyclophosphamide 1200 mg/m<sup>2</sup> D1, vindesine 2 mg/m<sup>2</sup> D1 and D5, bleomycine 10 mg D1 and D5 and prednisone D1 to D5) followed by a sequential consolidation consisting of HD methotrexate (2 courses), etoposide + ifosfamide (4 courses) and cytarabine (2 courses) at 2 weeks intervals.
  • Bortezomib 1.5 mg/m<sup>2</sup> was administered at D1 and D5 of each ACVBP cycle, and then at D1, D8 and D15 every 4 weeks during consolidation phase for a total of 20 injections during the whole treatment.
  • RESULTS: 57 eligible pts (M 38, F 19, median age 52.5 yrs) with mostly AITL and PTCL NOS subtypes were enrolled between January 2006 and November 2007; 78% had stage III-IV disease and 53% had aaIPI ≥ 2.
  • Forty six pts (81%) have completed induction treatment with ACVBP and only 28 (49%) the consolidation phase, mainly for disease progression.
  • As of November 14<sup>th</sup>, 2008, 22 pts (39%) have died, mostly from lymphoma.
  • The median percentage of planned dose of bortezomib received was 98% during ACVBP induction where the vinca alkaloid used was vindesine, and ranged from 90 to 95% during the consolidation courses.
  • The dose intensity of bortezomib was 84.3% during induction, similar to that of doxorubicine and cyclophosphamide.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960989.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Binh NN, Chevreau C, Penel N, Bay J, Coindre J, Mathoulin-Pelissier S, Ray-Coquard I, Italiano A, Genève J, Blay J: Consolidation with high-dose chemotherapy for responding patients to standard chemotherapy in advanced, metastatic soft tissue sarcoma (STS): A randomized trial from FNCLCC-French Sarcoma Group. J Clin Oncol; 2009 May 20;27(15_suppl):10505

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Consolidation with high-dose chemotherapy for responding patients to standard chemotherapy in advanced, metastatic soft tissue sarcoma (STS): A randomized trial from FNCLCC-French Sarcoma Group.
  • : 10505 Background: Whether high dose (HD) chemotherapy improves disease-free (DFS) or overall (OS) survival has been suggested in phase II trial, but never explored in a randomized setting.
  • This randomized, open, phase III study was designed to assess whether or not an HD chemotherapy with peripheral blood stem cells (PBSC) would improve OS in patients with advanced or metastatic STS responding to MAID chemotherapy.
  • After 4 courses of MAID, patients in PR or CR, or in whom complete surgical removal of all lesions was performed, were proposed for randomisation between 2 more cycles of MAID (control arm) vs 1 MAID followed by an intensification with MICE, ie: mesna (3.6g/m2, d1-5), ifosfamide (4g/m2, d1-4), carboplatin (UCA5, d2-4) and etoposide (300mg/m2, d1-4), followed by PBSC (HD arm).
  • RESULTS: From 03/00 to 06/08, 266 patients were included and 87 were randomised (15 centres); low accrual and new treatment concepts lead to an IDMC in 11/08 who analysed 45 treated in the control arm (41 with full treatment) and 40 in the HD arm [only 21 received MICE, because consent withdrawal (6), insufficient PBSC harvest (5), tumor reprogression (4)].
  • With a 39 months follow-up, 25 pts were alive in the control arm, and 19 in the HD arm.
  • The 3 years OS was 45.5% for control arm versus 35.8 for HD arm (HR = 1.12; 95% CI 0.58, 2.14; p = 0.72 Intention to treat analysis); PFS was 29.9% and 12.1 respectively (HR = 1.48; 95% CI 0.87, 2.53; p = 0.14).
  • Higher rate of grade 3 - 4 hematologic (87% vs 46%), and digestive toxicity (33% vs 0%) were observed in the HD arm.
  • Two treatment-related deaths occurred, both in the HD arm.
  • CONCLUSIONS: In this study, HD chemotherapy for STS patients didn't improve OS and DFS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963694.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Corazzelli G, Frigeri F, Marcacci G, Capobianco G, Arcamone M, Becchimanzi C, Russo F, Pinto A: Rituximab plus gemcitabine, ifosfamide, oxaliplatin (R-GIFOX) as salvage therapy for recurrent Hodgkin lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8579

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab plus gemcitabine, ifosfamide, oxaliplatin (R-GIFOX) as salvage therapy for recurrent Hodgkin lymphoma.
  • : 8579 Background: Gemcitabine (G), ifosfamide (Ifo), oxaliplatin (Ox) and rituximab (R) have been accounted of cross-synergy in preclinical and early clinical studies in Hodgkin lymphoma (HL).
  • We assessed activity, toxicity and stem cells (SCs) mobilizing capacity of a bi-weekly salvage combination with these agents in HL recurring after conventional or high dose therapy (HDT).
  • R-GIFOX consisted of R 375 mg/m<sup>2</sup> D1, G 1000 mg/m<sup>2</sup> D2, Ox 130 mg/m<sup>2</sup> D3 and Ifo 5 g/m<sup>2</sup> D3, as a 24-h single infusion, G-CSF 5 mcg/kg/d DD 7-11 (10 mcg/kg/d, 3rd course until SCs mobilization).
  • RESULTS: Twenty-one patients (median age 33 yrs, r 22-64) with relapsed (n = 16) [post-ASCT (n=6), <12 mo.s (n=7), > 12 mo.s (n=3)] or primary progressive (n = 5) HL, were prospectively accrued.
  • Ten patients (48%) had received ≥ 2 previous CHT lines and 15 (78%) had GHLSG recurring HL prognostic score ≥ 2.
  • Actual dose intensity of the first 3 courses was 82%, 86%, 92 % for G, Ifo and Ox, respectively.
  • At a median f.u. of 12 mo.s for CRs, Disease Free Survival was 79% in patients eligible for ASCT and 41% in those unfit treated with additional R-GIFOX.
  • CONCLUSIONS: R-GIFOX retains an attractive therapeutic potential in recurring HL, enabling pre-ABMT cytoreduction and mobilization, and also a safe delivery of a full salvage program to patients unfit for HDT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962276.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Goldman S, Coiffier B, Reiter A, Younes A, Cairo MS, International TLS Expert Panel: A medical decision tree for the prophylaxis (P) and treatment (T) of tumor lysis syndrome (TLS): An international TLS consensus panel. J Clin Oncol; 2009 May 20;27(15_suppl):e17575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A medical decision tree for the prophylaxis (P) and treatment (T) of tumor lysis syndrome (TLS): An international TLS consensus panel.
  • : e17575 Background: We (MC) previously established a definition of laboratory (LTLS) and clinical TLS (CTLS) and associated grading system (Cairo et al, BJH. 2004).
  • Additionally, we recently reported an evidence based review of guidelines for the P and T of TLS (Coiffier et al, J Clin Oncol. 2008).
  • METHODS: We convened an international panel (N = 17) of experts in pediatric and adult hematological malignancies and solid tumors (ST) to develop a medical decision tree for the P and T of TLS based on the risk classification (low, medium, high) and management recommendations of Coiffier et al (J Clin Oncol.
  • 2008) Results: Patients without evidence of LTLS were assigned to either low-risk disease (LRD), medium-risk (MRD), or high-risk (HRD).
  • Risk factors included pathological classification stage, bulk, disease burden (WBC/LDH) and renal impairment/involvement.
  • HRD was assigned to patients with either B-ALL, ALL/AML ≥100K/mm<sup>3</sup>, BL/LL stage III/IV, and/or high LDH, DLBCL/PTCL/MCL/ATL with bulky and elevated LDH and patients with MRD with renal impairment/involvement.
  • MRD consisted of ALL ≤100K/mm<sup>3</sup>, AML 25-100K/mm<sup>3</sup>, BL/LL stage I/II and low LDH, childhood ALCL, DLBCL/PTCL/MCL/ATL non-bulky but elevated LDH, CLL treated with targeted therapy, and LRD with renal impairment/involvement.
  • LRD consisted of ST (except bulky sensitive to cytotoxic therapy [MRD]), CML, MM, HL, other NHL and AML <25K/mm<sup>3</sup>.
  • CONCLUSIONS: This medical decision tree will facilitate the practice of management of the P and T of TLS and hopefully improve the quality of care in a cost effective manner.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963935.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Macedo CR, Cappellano AM, Noguchi DT, Martinho AP, Dias CG, Dias CG, Malheiros RC, Dutra AH, Grings M, Pires AL, Petrilli AS: Outpatient administration of high-dose methotrexate for osteosarcoma treatment in Brazil. J Clin Oncol; 2009 May 20;27(15_suppl):10038

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outpatient administration of high-dose methotrexate for osteosarcoma treatment in Brazil.
  • : 10038 Background: We describe the experience with outpatient administration of high dose methotrexate (HDMTX) and leucovorin rescue for osteosarcoma treatment at Instituto de Oncologia Pediátrica.
  • Families were oriented to measure urinary pH and volume, PO intake and to adjust leucovorin dose as needed.
  • Concomitantly to HD chemotherapy, low dose oral cyclophosphamide and MTX (metronomic treatment) were provided to metastatic (M) patients.
  • The main differences found between M and non-M patients were 16.8% versus 8.7% of leucopenia grade IV and 12.1% versus 6.6% of anemia grades III and IV.
  • CONCLUSIONS: Similar to other authors' experience, outpatient administration of HDMTX lead to elevated serum levels in 42.5% of the infusions, demonstrating the importance of a well trained staff and early introduction of supportive therapies to avoid associated toxicities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962549.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Patel R, Kurian S, Sun C, Francisco L, Wong L, Sharp J, Armenian S, Forman S, Bhatia S: Challenges for retrospective cohort studies: A profile of patients who refuse participation or are lost to follow-up. J Clin Oncol; 2009 May 20;27(15_suppl):6615

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 6615 Background: As hematopoietic cell transplantation (HCT) has increasingly become a curative option for many diseases, studying long-term complications has assumed critical importance.
  • Sociodemographic and clinical characteristics indicative of higher risks for refusal or LTFU were identified.
  • Primary diagnoses included acute/chronic leukemia (43%), Hodgkin/non-Hodgkin lymphoma (36%), multiple myeloma (9%), and other miscellaneous diagnoses (12%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961771.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Quinaux EM, Baumgaertner I, Khalil A, Louvet C, Buyse ME, de Gramont A, André T: Comparison of l and dl forms of folinic acid in Gercor C96.1 trial (A phase III trial comparing bimonthly LV5FU2 to monthly high-dose 5FU-leucovorin in patients with Dukes' B2 and C colon cancer). J Clin Oncol; 2009 May 20;27(15_suppl):e15004

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of l and dl forms of folinic acid in Gercor C96.1 trial (A phase III trial comparing bimonthly LV5FU2 to monthly high-dose 5FU-leucovorin in patients with Dukes' B2 and C colon cancer).
  • 2007 20;25:3732-8), patients were randomized to either monthly 5FU-LV hd (dl LV 200 mg/m<sup>2</sup> or l LV 100 mg/m<sup>2</sup> 15 min iv followed by 5FU 400 mg/m<sup>2</sup> 15 min iv, d1-5 q4 wk) or LV5FU2 (dl LV 200 mg/m<sup>2</sup> or l LV 100 mg/m<sup>2</sup> 2-hour infusion followed by iv bolus 5FU 400 mg/m<sup>2</sup> and 22 hours continuous infusion 600 mg/m<sup>2</sup>, d1 and d2 q 2 wk).
  • There were no statistically significant differences between l and dl forms in term of disease free survival (33.3% vs 32.8% of patients with at least one event in l and dl forms respectively, hazard ratio=1.03, 95% CI=[0.82-1.31], p=0.78).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964361.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Malogolowkin MH, Krailo M, Frazier LA, Olson TA: Study of cisplatin, etoposide, bleomycin, and escalating dose cyclophosphamide therapy for children with high-risk germ cell tumors: A Children's Oncology Group report. J Clin Oncol; 2009 May 20;27(15_suppl):10035

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of cisplatin, etoposide, bleomycin, and escalating dose cyclophosphamide therapy for children with high-risk germ cell tumors: A Children's Oncology Group report.
  • : 10035 Background: In the intergroup high-risk germ cell tumors (HR-GCT) study (CCG-8882/POG-9049) patients with extragonadal GCT treated with high-dose cisplatin, etoposide, and bleomycin (HD-PEB) had a 2 year-EFS of 84% versus 74% for those treated with standard PEB (PEB), suggesting that treatment intensification might be beneficial.
  • The goal of this study was to establish the maximum tolerated dose (MTD) and toxicity profile of cyclophosphamide combined with PEB in untreated patients with HR-GCT.
  • METHODS: From July 2004 to August 2007, 19 eligible children and adolescents with stage III/IV extragonadal GCT received cisplatin 20 mg/m<sup>2</sup>/day × 5, etoposide 100 mg/m<sup>2</sup>/d × 5, bleomycin 15 mg/m<sup>2</sup> on d1, and escalating doses of cyclophosphamide (1.2, 1.8 or 2.4 g/m<sup>2</sup>) on d1.
  • DLT was defined as any grade 4 non-hematologic toxicity other than nausea and vomiting, fever and infection, and any non-hematologic grade 3 toxicity which had not reversed (< grade 2) within 28 days of treatment; or hematologic toxicity grade 3 or 4, which despite hematopoietic growth factor support, was not reversible within 28 days of treatment.
  • Fifteen of the 19 patients were removed from protocol therapy after 4 cycles of therapy; 11 were disease-free, 2 electively terminated protocol therapy, 1 patient was lost to follow-up, and 1 had progressive disease (PD).
  • Four patients received 2 more cycles of C-PEB, of these 3 were disease-free and 1 had PD.
  • CONCLUSIONS: The addition of cyclophosphamide to the standard PEB regimen is feasible and well tolerated at all dose levels used on this study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962582.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Zhang M, Huck J, Hyer M, Ecsedy J, Manfredi M: Effect of Aurora A kinase inhibitor MLN8237 combined with rituximab on antitumor activity in preclinical B-cell non-Hodgkin's lymphoma models. J Clin Oncol; 2009 May 20;27(15_suppl):8553

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of Aurora A kinase inhibitor MLN8237 combined with rituximab on antitumor activity in preclinical B-cell non-Hodgkin's lymphoma models.
  • In this study we explored the anti-tumor effect of MLN8237 in vivo in pre-clinical models of human Diffuse Large B-cell Lymphoma (DLBCL) both as a single agent and in combination with the anti-CD20 monoclonal antibody Rituximab.
  • RESULTS: MLN8237 induced anti-tumor activity that was dose-dependent in all three models.
  • In the primary lymphoma model, MLN8237(10-20mg/kg) caused a significant anti-tumor effect during treatment period (TGI = 83-95%).
  • MLN8237 is currently being tested as a single agent in a phase I clinical trail in patients with DLBCL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960986.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Andorsky DJ, Yamada R, Steward K, De Vos S, Said J, Timmerman J: Expression of programmed death ligand 1 (PD-L1) by non-Hodgkin's lymphomas (NHL) and effect on tumor-associated T cells. J Clin Oncol; 2009 May 20;27(15_suppl):8526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of programmed death ligand 1 (PD-L1) by non-Hodgkin's lymphomas (NHL) and effect on tumor-associated T cells.
  • : 8526 Background: PD-L1 is expressed on antigen presenting cells and inhibits activation of T cells through its receptor, PD-1.
  • METHODS: PD-L1 expression was analyzed in 16 NHL cell lines by flow cytometry (FC) and in 111 lymphoma specimens by immunohistochemistry (IHC) (n=92) or FC (n=19).
  • In functional studies, irradiated anaplastic large cell lymphoma (ALCL) cells were co-cultured with allogeneic T cells in the presence of anti-PD-L1 blocking antibody, and IFNγ secretion and thymidine incorporation was used to assess T cell function and proliferation.
  • To further test tumor-T cell interactions, malignant ascites from a patient with ALK+ ALCL and peripheral blood mononuclear cells from a patient with leukemic mantle cell lymphoma, both containing PD-L1-expressing tumor cells and tumor-associated T cells, were stimulated with phytohemagglutinin (a polyclonal T cell activator) and incubated with anti-PD-L1 antibody.
  • Levels of 16 inflammatory cytokines were measured as an assessment of T cell activity.
  • RESULTS: All 9 B cell lymphoma lines were negative for PD-L1, while all 5 ALCL cell lines were strongly positive.
  • One T-cell ALL line was positive, and one peripheral T cell lymphoma was negative.
  • Strong PD-L1 staining was detected by IHC in all 14 ALCL specimens and in 83% of diffuse large B cell lymphomas (DLBCL) analyzed (n=35).
  • In the autologous setting using cultures of ALCL and mantle cell lymphoma specimens containing host T cells, secretion of inflammatory cytokines by tumor-associated T cells, including GMCSF, IFNγ, IL-1, IL-6, IL-8, TNFα, and MIP1α, were increased by incubation with anti-PD-L1 antibody.
  • PD-L1 may play a role in thwarting an effective anti-tumor immune response and represents an attractive target for lymphoma immunotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960901.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Pettengell R, Narayanan G, Mendoza FH, Digumarti R, Gomez H, Cernohous P, Gorbatchevsky I: Randomized phase III trial of pixantrone compared with other chemotherapeutic agents for third-line single-agent treatment of relapsed aggressive non-Hodgkin's lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8523

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase III trial of pixantrone compared with other chemotherapeutic agents for third-line single-agent treatment of relapsed aggressive non-Hodgkin's lymphoma.
  • Pixantrone, a novel aza-anthracenedione with structural similarities to mitoxantrone, has potentially reduced cardiotoxicity and has demonstrated promising clinical activity in phase II studies in heavily pretreated NHL patients.
  • METHODS: PIX301 was a controlled, multicenter, open-label phase III study of ≥ third-line treatment of relapsed aggressive (de novo or transformed) NHL.
  • All patients were required to have received ≥ 1 prior anthracycline-containing regimen, with the cumulative doxorubicin-equivalent dose limited to ≤ 450 mg/m<sup>2</sup>.
  • Randomization was to pixantrone 85 mg/m<sup>2</sup> on days 1, 8 and 15 of 28-day cycles, for up to 6 cycles, or to investigator's choice of a single-agent comparator (vinorelbine, oxaliplatin, ifosfamide, etoposide, or mitoxantrone; in the US only, gemcitabine and rituximab were permitted).
  • CONCLUSIONS: In this study, single-agent therapy with pixantrone achieved significantly superior CR/CRu and ORR rates in ≥ third-line treatment of relapsed/refractory aggressive NHL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960900.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Hoffman KR: Understanding among medical oncologists of the true monetary cost of therapy. J Clin Oncol; 2009 May 20;27(15_suppl):6629

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: 50 medical oncologists agreed to take a survey judging their knowledge of the financial cost of the treatments used in patients with the five most common tumors treated in the office: breast cancer, non-small cell lung cancer, colorectal cancer, non-Hodgkin's lymphoma, and three other commonly treated cancers: chronic myelogenous leukemia, multiple myeloma and ovarian cancer.
  • Treatment regimens in the adjuvant and first line metastatic setting were used.
  • They were asked to calculate the cost based a patient completing their adjuvant therapy or treatment in the first-line metastatic setting, which was defined by each practicioner.
  • More education is needed in the economics, including monetary cost-benefit analysis, of oncology practice so that we can better serve our patients and society.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961808.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Townsend AR, Millward M, Price T, Mainwaring P, Spencer A, Longenecker A, Palladino MA, Lloyd GK, Spear MA, Padrik P: Clinical trial of NPI-0052 in advanced malignancies including lymphoma and leukemia (advanced malignancies arm). J Clin Oncol; 2009 May 20;27(15_suppl):3582

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical trial of NPI-0052 in advanced malignancies including lymphoma and leukemia (advanced malignancies arm).
  • : 3582 Background: The novel structure (non-peptide based) of NPI-0052 (NPI) appears to lead to unique proteasome inhibition (PI), toxicology and signal transduction profiles.
  • Preclinical research suggests improvements in therapeutic ratio and activity in hematologic and solid tumor models, leading to clinical trials in patients with myeloma, lymphomas, leukemias, and solid tumors.
  • METHODS: Patients with solid tumor, lymphoma or leukemia diagnoses without standard treatment options were treated with IV NPI on Days 1, 8 and 15 of 28-day cycles in a 3+3 design dose escalation to a Recommended Phase 2 Dose (RP2D).
  • Enrollment then began in 10 patient lymphoma and CLL RP2D cohorts.
  • RESULTS: 30 patients were treated at doses ranging from 0.1 mg/m<sup>2</sup> to 0.9 mg/m<sup>2</sup>.
  • At the RP2D fatigue, parosmia/dysgeusia, transient peri-infusion site pain and lymphopenia were commonly ascribed to NPI.
  • PI was assayed in blood, indicating a dose:response relationship with mean inhibition of chymotrypsin-like activity up to of 88% Day 1 and 100% Day 15, and inhibition of caspase-like and trypsin-like activity of up to 51% and 72%.
  • PI remained between doses in whole blood (RBC), but recovered between doses in PBMC.
  • Stable disease was induced in 31% of patients, including one each with mantle cell, Hodgkin's lymphoma, follicular lymphoma, sarcoma, prostate carcinoma, and two with melanoma.
  • CONCLUSIONS: NPI-0052 produces dose-dependent pharmacologic effects through the predicted efficacious range to an MTD, while producing a toxicity profile that is tolerable and dissimilar to bortezomib in spite of reaching higher PI levels.
  • These data indicate potential for a greater range of uses than other proteasome inhibitors and lead to additional studies being initiated in hematologic malignancies and solid tumors alone and in combination.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961753.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Sohn B, Yoon D, Kim S, Lee D, Kim S, Huh J, Lee J, Suh C: Outcomes in patients with primary gastric diffuse large B-cell lymphoma after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):e19543

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes in patients with primary gastric diffuse large B-cell lymphoma after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy.
  • : e19543 Background: The optimal therapy for primary gastric diffuse large B- cell lymphoma (DLBCL) still needs to be defined.
  • METHODS: We searched AMC Registry for Non-Hodgkin's Lymphoma and found 26 patients with primary gastric DLBCL, who received R-CHOP as first-line chemotherapy.
  • Ten of 26 patients had localized disease.
  • Remaining patients had disseminated disease.
  • After analyses of 10 patients with localized disease, we found that these patients had received a total 38 cycles, with a median of 3 cycles per patient.
  • Of 10 patients, one patient had 2 cycles of R-CHOP, 4 had 3 cycles, and one had 4 cycles, all 6 patients above followed by consolidation radiotherapy.
  • Remaining one patient and 4 patients had 5 cycles and 6 cycles of R-CHOP, respectively.
  • In patients with localized disease, CR was observed in 10 of 10 patients (100%), and both 3-year EFS and OS was 100% (10 of 10 patients).
  • In analyses with 16 patients with disseminated disease, all patients had received a total 91 cycles, with a median of 6 cycles per patient.
  • CR after R-CHOP treatment was observed in 10 of 16 patients (62.5%), partial response in 3 patients, stable disease in 1 patient, and progressive disease in 1 patient.
  • Three-year EFS and OS was 61.1% and 57.8% in patients with disseminated disease.
  • Combination with rituximab in CHOP regimen showed excellent prognosis especially in patients with localized disease.
  • In localized disease, CR was 100%, 3-year EFS and OS was 100%.
  • In disseminated disease, CR was 62.5%, 3-year EFS and OS was 61.1% and 57.8%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960994.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Gerecitano JF, O'Connor O, Van Deventer H, Hainsworth J, Leonard J, Afanasayev B, Chen M, Seroogy J, Escandon R, Wolff A, Conlan M: A phase I/II trial of the kinesin spindle protein (KSP) inhibitor SB-743921 dosed q14d without and with prophylactic G-CSF in non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL). J Clin Oncol; 2009 May 20;27(15_suppl):8578

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II trial of the kinesin spindle protein (KSP) inhibitor SB-743921 dosed q14d without and with prophylactic G-CSF in non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL).
  • Eligible patients (pts) have relapsed or refractory HL or NHL, aggressive (a) or indolent (i), have had at least 1 prior chemotherapy (CT) regimen, and have relapsed after or were not candidates for stem cell transplant.
  • This is a standard 3+3 dose escalation trial design, starting at 2 mg/m<sup>2</sup> and escalating by 1 mg/m<sup>2</sup>.
  • RESULTS: 39 pts were treated (-GCSF) at 6 dose levels (2-7 mg/m<sup>2</sup>).
  • For all 51 pts treated to date, mean age was 52 yr; 53% were male; 39% HL, 33% aNHL, and 28% iNHL; 76% had ≥3 prior CT regimens.
  • There were 2 partial responses (PR), both in elderly pts with HL with ≥2 prior CT regimens, 1 at 6 (-GCSF) and 1 at 8 (+GCSF) mg/m<sup>2</sup>, ongoing at Cycle 4+.
  • This dose density (0.43 mg/m<sup>2</sup>/d) is >2-fold higher than in the FIH trial with a q21d schedule (0.19 mg/m<sup>2</sup>/d).
  • Dose escalation (+GCSF) is continuing.
  • Activity has been observed in HL, with 2 PRs at doses ≥6 mg/m<sup>2</sup>.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962277.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Cocorocchio E, Vanazzi A, Botteri E, Alietti A, Negri M, Bassi S, Preda L, Travaini L, Peccatori FA: Prognostic role of interim &lt;sup&gt;18&lt;/sup&gt;FDG-PET in Hodgkin lymphoma: A single-center experience. J Clin Oncol; 2009 May 20;27(15_suppl):e19520

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic role of interim <sup>18</sup>FDG-PET in Hodgkin lymphoma: A single-center experience.
  • : e19520 Background: The role of FDG-PET for staging and response assessment in Hodgkin lymphoma (HL) is still evolving.
  • METHODS: We retrospectively analysed 65 consecutive pts affected by newly diagnosed HL.
  • Histology included 50 classical and 10 lymphocyte predominance HL.
  • 30/65 pts showed good prognosis (defined as IA-IIA, < 3 nodal sites, ERS < 50) and received 4 cycles of VBM followed by involved field (IF) radiotherapy (RT); the remaining 35 pts received hybrid ChlVPP/ABVVP for 6 cycles followed by IF RT in case of bulky disease.
  • All patients underwent <sup>18</sup>FDG-PET scans at diagnosis, after the fourth cycle in the VBM group, after the third cycle in the ChlVPP/ABVVP (interim <sup>18</sup>FDG-PET), at the end of treatment in all patients.
  • CONCLUSIONS: In our experience interim <sup>18</sup>FDG-PET demonstrate a predictive role regarding the achievement of CR and treatment failure, at least as relevant as Hasenclever index, but failed to predict clinical result in 12 (18%) pts.
  • Its role in defining the best therapeutical approach in HL pts must be further investigated in randomized clinical trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960937.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Gil Deza E, Dragosky M, Annetta I, Marquez M, Corzo A, Gercovich N, Morgenfeld E, Tognelli F, Rivarola E, Gercovich FG: Primary breast lymphomas: An Argentinian cooperative study. J Clin Oncol; 2009 May 20;27(15_suppl):e19555

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary breast lymphomas: An Argentinian cooperative study.
  • : e19555 Background: Primary Breast Lymphomas are rare tumors (less than 1% of all primary breast tumors).
  • Because of that, the records of two institutions dedicated exclusively to the treatment of cancer (Hospital Municipal de Oncologia "Maria Curie" and Instituto Oncologico Henry Moore) have been working together in a single series.
  • OBJECTIVE: To make a retrospective study of the clinical onset, treatment and evolution of the patients with Primary Breast Lymphoma (PBL).
  • A database containing characteristics of the population, clinical onset, treatments, evolution and survival Results: Gender F/M=2/15 pt.
  • Pathology: Hodgkin's Lymphoma = 1 pt, NHL follicular = 8 pt, Large-Cell Diffuse NHL = 6 pt, lymphoplasmocytic NHL = 1 pt, Marginal Zone NHL = 1 pt.
  • 2) Sixteen out of 17 were non-Hodgkin lymphomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961091.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Villano JL, Letarte N, Yu JM, Shakir AR, Bressler L: Hematologic adverse events associated with temozolomide (TMZ). J Clin Oncol; 2009 May 20;27(15_suppl):2053

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2053 Background: Secondary acute myeloid leukemia (AML) is reported to occur in 3%-10% of patients treated with alkylating agents for Hodgkin's lymphoma, non-Hodgkin's lymphoma, ovarian cancer, breast cancer, and multiple myeloma.
  • Chemotherapy induced aplastic anemia is usually dose-related versus an idiosyncratic mechanism.
  • Among these patients, we identified 140 cases that we labeled as major hematologic adverse events: agranulocytosis (8 cases), aplasia (42), aplastic anemia (52), leukemia (26), MDS (6), and lymphoma (6).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964671.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Ferreri AJ, Reni M, Martelli M, Pangalis G, Frezzato M, Cabras G, Fabbri A, Corazzelli G, Zucca E, Cavalli F: Randomized phase II trial on primary chemotherapy with high-dose methotrexate (HD-MTX) alone or associated with high-dose cytarabine (HD-araC) for patients with primary CNS lymphoma (I.E.L.S.G. #20 Trial): Tolerability, activity, and survival analyses. J Clin Oncol; 2009 May 20;27(15_suppl):8545

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II trial on primary chemotherapy with high-dose methotrexate (HD-MTX) alone or associated with high-dose cytarabine (HD-araC) for patients with primary CNS lymphoma (I.E.L.S.G. #20 Trial): Tolerability, activity, and survival analyses.
  • : 8545 Background: HD-MTX-based chemotherapy (cht) is the conventional approach to primary CNS lymphoma (PCNSL), but superiority of polycht over HD-MTX alone is unproven.
  • A benefit of adding HD-araC to MTX has been suggested.
  • This is a randomized phase II trial comparing HD-MTX monocht versus HD-MTX plus HD-araC as primary cht in immunocompetent patients (pts) with PCNSL.
  • METHODS: 79 HIV- pts with newly diagnosed PCNSL, age 18-75 ys, ECOG-PS≤3, and measurable disease were randomly assigned to receive 4 courses (interval 3 weeks) of MTX 3.5 g/mq (control arm; n=40) or MTX (same dose) + araC 2 g/mq × 2/d, d 2-3 (experimental arm; n=39).
  • No differences in clinical presentation between arms were observed.
  • Causes of cht interruption were: progressive disease in 20 MTX and 8 MTX+araC pts, toxicity in 1 MTX and 7 MTX+araC pts and refusal in 2 MTX+araC pts.
  • All G3-4 non-hematological toxicities were <5%.
  • The addition of HD-araC to HD-MTX resulted in significantly better outcome and acceptable toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960962.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Flinn IW, Byrd JC, Furman RR, Brown JR, Lin TS, Bello C, Giese NA, Yu AS: Preliminary evidence of clinical activity in a phase I study of CAL-101, a selective inhibitor of the p1108 isoform of phosphatidylinositol 3-kinase (P13K), in patients with select hematologic malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):3543

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary evidence of clinical activity in a phase I study of CAL-101, a selective inhibitor of the p1108 isoform of phosphatidylinositol 3-kinase (P13K), in patients with select hematologic malignancies.
  • In vitro studies of 0.1 to 10 μM CAL-101 showed inhibition of pAKT expression and/or apoptotic effects against primary chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) cells and against a range of leukemia and lymphoma cell lines.
  • METHODS: In an ongoing phase 1 dose escalation study in sequential cohorts of 3 patients with relapsed/refractory CLL or select B-cell non-Hodgkin's lymphoma, CAL-101 is administered orally twice daily for 28 days per cycle.
  • Clinical response is evaluated according to NCI criteria at the end of Cycles 1 and 2 and every 2 cycles thereafter.
  • RESULTS: To date, 6 patients have been treated in the first 2 cohorts at dose levels of 50 mg and 100 mg and the 200 mg cohort is currently enrolling.
  • Two of 6 patients attained partial response and 4 have stable disease.
  • Partial responses were observed after 2 cycles of 50 mg in a patient with mantle cell lymphoma with 6 prior therapies, and after 1 cycle of 100 mg in a patient with follicular lymphoma with 6 prior therapies, including autologous stem cell transplant.
  • Disease specific cohort expansion will occur at the maximally tolerated dose, and patients with AML will be added.
  • CONCLUSIONS: Early results from a phase 1 study of the oral PI3K p110δ inhibitor CAL-101 show that it is well tolerated and has preliminary clinical activity in patients with B-cell malignancies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961357.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Diehl V, Haverkamp H, Mueller R, Mueller-Hermelink H, Cerny T, Markova J, Ho AD, Kanz L, Greil R, Engert A: Eight cycles of BEACOPP escalated compared with 4 cycles of BEACOPP escalated followed by 4 cycles of BEACOPP baseline with or without radiotherapy in patients in advanced stage Hodgkin lymphoma (HL): Final analysis of the HD12 trial of the German Hodgkin Study Group (GHSG). J Clin Oncol; 2009 May 20;27(15_suppl):8544

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eight cycles of BEACOPP escalated compared with 4 cycles of BEACOPP escalated followed by 4 cycles of BEACOPP baseline with or without radiotherapy in patients in advanced stage Hodgkin lymphoma (HL): Final analysis of the HD12 trial of the German Hodgkin Study Group (GHSG).
  • : 8544 Background: The GHSG HD9 trial had established BEACOPP escalated (BE) as new standard of care for advanced-stage HL patients.
  • The second question in this trial related to the need of additional radiotherapy (RT) to initial bulk and residual disease.
  • METHODS: HL patients in stage IIB with large mediastinal mass and/or E-lesions or stage III/IV were randomised according to a 2x2-factorial design between: 8BE + RT, 8BE no RT, 4BE+4BB + RT, 4BE+4BB no RT.
  • A total of 156 (9.9%) deaths (72 vs 84) have been observed (22 vs 32 acute or salvage treatment toxicity; 15 vs 24 HL; 22 vs 13 secondary neoplasia).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960959.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Jajeh A: Reccurent and prolonged panctopenia with rituximab therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e19550

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This drug has been implemented in the treatment of B cell lymphoproliferative disorders as well as non-neoplastic disease such as autoimmune thrombocytopenia, immune hemolytic anemia and other disorders related to overexpression of antibodies against the host.
  • One patient, a female( age 33) had rheumatoid arthritis and the rest had non hodgekin's lymphoma.
  • None of the patients with non hodgkin's lymphoma had bone marrow involvement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961092.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Naina HV, Pruthi RK, Litzow MR, Ansell SM, Dispenzieri A, Hogan WJ, Gertz MA, Elliott MA, Gastineau DA, Kumar SK: Low risk for symptomatic venous thromboembolic events (vte) during cytokine administration for peripheral blood stem cell mobilization. J Clin Oncol; 2009 May 20;27(15_suppl):7039

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We included only patients with a diagnosis of AL amyloidosis (AL), multiple myeloma (MM) Hodgkin's lymphoma (HL) and non Hodgkin's lymphoma (NHL).
  • Patients' demographic details and diagnosis of VTE were collected from electronic medical records.
  • Of the 631 patients, 278 (44%) MM, 209 (33%) NHL, 114 (18%) AL, and 20 (3%) had HL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961413.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Kamper P, Bendix K, Hamilton-Dutoit S, Honoré B, d'Amore F: Tumor-infiltrating CD163-positive macrophages, clinicopathological parameters, and prognosis in classical Hodgkin lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8528

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-infiltrating CD163-positive macrophages, clinicopathological parameters, and prognosis in classical Hodgkin lymphoma.
  • : 8528 Background: Classical Hodgkin lymphoma (cHL) is characterized by a minority of neoplastic cells surrounded by a heterogeneous background of non-neoplastic cells.
  • A possible prognostic role of LAMs in cHL and follicular lymphomas has been suggested.
  • The aim of the present study was to correlate the expression of the tumor-infiltrating CD163+ LAMs with clinico-pathological features and prognosis in a cohort of previously untreated HL patients (pts).
  • METHODS: A tissue microarray (TMA) was constructed with paraffin embedded tissue specimens from 286 cHL cases.
  • Clinical data were obtained from the Danish population-based lymphoma registry and clinical records.
  • All pts were homogeneously treated with either chemo-radiotherapy (localised disease) or ABVD chemotherapy (advanced disease).
  • The histological subtypes were: nodular sclerosis (NS)-type I, 167 cases (59 %); NS-type II, 71 (25%); mixed cellularity (MC), 44 (15 %); lymphocyte-rich, lymphocyte-depleted and cHL-NOS, each one case.
  • Of 253 pts with assessable International Prognostic Score (IPS), 204 had a low-risk (≤ 2) and 49 a high risk (>2) profile.
  • Furthermore, a high expression of CD163 strongly correlated to stage IV disease (p=0.035), presence of B-symptoms (p=0.008), lymphocytopenia (p=0.003), hypersedimentation (p=0.009).
  • CONCLUSIONS: In cHL, a high number of intratumoral CD163+ monocytes/macrophages correlates with adverse outcome and with clinical parameters reflecting underlying aggressive disease biology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960903.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Blum KA, Smith M, Fung H, Zalevsky J, Combs D, Ramies DA, Younes A: Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: Safety, pharmacokinetics (PK), immunogenicity, and efficacy. J Clin Oncol; 2009 May 20;27(15_suppl):8531

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: Safety, pharmacokinetics (PK), immunogenicity, and efficacy.
  • : 8531 Background: XmAb2513 is a novel 2<sup>nd</sup>-generation humanized monoclonal antibody (mAb) directed against CD30 (a cell surface antigen expressed on Reed-Sternberg cells of HL and ALCL), with an Fc region engineered to have increased binding affinity to Fcγ receptors (FcγRs) leading to improved FcγR-dependent effector cell functions.
  • In cynomolgus monkeys (cynos), XmAb2513 exposure was dose-proportional with half-lives ranging from 12 - 17d in repeat dose studies, which suggested biweekly (QOW) dosing in man.
  • A Phase 1 study has been initiated to examine the safety and efficacy of XmAb2513 in patients (pts) with relapsed HL and ALCL.
  • METHODS: Phase 1 open-label study with QOW dosing of XmAb2513; dose-escalation study design with doses of 0.3, 1, 3, 6, 9, and 12 mg/kg via IV-infusion to establish the maximum tolerated dose (MTD).
  • RESULTS: 13 HL pts have been enrolled in the 1<sup>st</sup> 4 dose levels (0.3 to 6 mg/kg).
  • 1 pt with an extensive treatment history and chronic immunosuppression died due to fungal pneumonia after a single 3 mg/kg dose.
  • PK parameters were computed for the 1<sup>st</sup> dose alone and for the entire course of XmAb2513 treatment.
  • PK parameters appeared non-linear across the dose range from 0.3 - 3 mg/kg.
  • XmAb2513 has demonstrated encouraging biologic activity in patients with refractory HL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960926.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Elkin EB, Gonzales AR, Ishill NM, Klem ML, Hodgson D, Ng AK, Marks LB, Weidhaas J, Freedman GM, Miller RC, Yahalom J: Synchronous and metachronous bilateral breast cancer: Are the risks greater in women with a history of radiation for Hodgkin lymphoma? J Clin Oncol; 2009 May 20;27(15_suppl):607

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous and metachronous bilateral breast cancer: Are the risks greater in women with a history of radiation for Hodgkin lymphoma?
  • : 607 Background: Women with a history of radiation therapy (RT) for Hodgkin lymphoma (HL) have an elevated risk of breast cancer (BC).
  • In particular, rates of synchronous and metachronous bilateral BC may be greater in patients with a history of RT for HL.
  • METHODS: Women diagnosed with BC between 1980 and 2006 following RT for HL were identified retrospectively from 8 institutions in North America.
  • Each patient in this cohort was matched with 3 BC patients with no history of HL, from the same institution, by age at BC diagnosis, year of BC diagnosis and race.
  • Information on patient and tumor characteristics, disease recurrence and new contralateral tumors was obtained from medical records.
  • RESULTS: 253 BC patients with a history of RT for HL were matched with 741 patients with sporadic BC.
  • The median interval between HL and first BC diagnosis was 19 years.
  • Median age at BC diagnosis was 44 years and median follow-up was 5 years from BC diagnosis.
  • Synchronous bilateral BC was diagnosed in 6% of the HL survivors and 2% of the matched patients with sporadic BC.
  • Among women with unilateral disease, 21% of HL survivors and 3% of sporadic BC patients had a bilateral mastectomy.
  • BC patients with a history of RT for HL had a greater rate of metachronous CBC (adjusted hazard ratio 3.3, 95% CI 2.1-5.8), controlling for patient, tumor and treatment characteristics.
  • CONCLUSIONS: Women who develop BC after RT for HL have more than 3 times the risk of CBC than similar women with sporadic BC.
  • Our findings support close follow-up for CBC in BC patients with a history of RT for HL and may inform decisions about prophylactic mastectomy in this population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961468.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Reiter A, Meinhardt A, Burkhardt B, Zimmermann M, Borkhardt A, Kontny U, Mann G, Schrappe M: Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin lymphoma (NHL). J Clin Oncol; 2009 May 20;27(15_suppl):10000

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin lymphoma (NHL).
  • Exclusion: Lansky performance scale 5, pre-treatment, impaired renal-, heart-, liver-function, hepatitis B, pre-existing disease, pregnancy.
  • RR by histology: BL/B-ALL 29/68, DLBCL 6/14, juvenile follicular lymphoma 1/2, PMBCL 1/1, B-NHL nfs 0/2.
  • Fifty pts were non-RPs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962545.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Von Drygalski A, Tran TB, Messer K, Pu M, Corringham S, Nelson C, Ball ED, Ball ED: Predictors of survival in patients with metastatic breast cancer (MBC) treated with high-dose chemotherapy and autologous stem cell transplantation (HD-ASCT). J Clin Oncol; 2009 May 20;27(15_suppl):e22086

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of survival in patients with metastatic breast cancer (MBC) treated with high-dose chemotherapy and autologous stem cell transplantation (HD-ASCT).
  • Although HD-ASCT has not resulted in improved overall survival (OS), retrospective analyses may identify patients who benefited.
  • We reviewed records of all patients (n=96) in the bone marrow transplant registry at UCSD treated with HD-ASCT for MBC between 1989 and 2000.
  • METHODS: Age, race, stage at diagnosis, histology, estrogen receptor (ER) and menopausal status, body mass index (BMI) in kg/m2, time to transplant and death, sites of metastasis, disease status prior to and after transplant, and days in hospital were extracted.
  • Brookmeyer & Crowley's 95% confidence intervals, Cox models for predictors of a time-to-event variable and Schoenfeld tests for proportional hazard assumptions were applied.
  • RESULTS: Median OS was 5.6 ys (CI 4.1-7.4) after initial diagnosis and 1.7 ys (CI 1.36-2.07) after transplant.
  • OS after HD-ASCT at 12 ys was 8.2% and, although not statistically significant, 18.5% in ER- and 2.6% in ER+ patients, respectively.
  • Stratified by ER status, stage at diagnosis was an independent predictor of OS.
  • Patients with stage I at diagnosis were at lowest risk of death when compared to stage II-IV patients with HRs of 2.7 (II vs I CI 1.4-5.2), 4.6 (III vs I CI 2.1-10) and 17 (IV vs I CI 6.1- 47.8).
  • CONCLUSIONS: The study highlights that ∼10% of patients experience ≥10 ys survival with HD- ASCT.
  • Obesity, late stage at diagnosis, lobular infiltrating histology and visceral metastasis were independent negative predictors of OS.
  • Although survival was influenced by various disease characteristics, obesity was the only significant patient derived factor.
  • These data may be useful stratification tools for future trials employing HD-ASCT as treatment modality in MBC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963264.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Zain JM, Foss F, Kelly WK, DeBono J, Petrylak D, Narwal A, Neylon E, Blumenschein G, Lassen U, O'Connor OA: Final results of a phase I study of oral belinostat (PXD101) in patients with lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8580

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Final results of a phase I study of oral belinostat (PXD101) in patients with lymphoma.
  • A phase I of oral Bel in patients (pts) with solid tumors found a recommended dose for day (d) 1-14, q3w, of 750 mg QD, with option for intra-patient dose escalation if limited toxicity.
  • The current study was initiated to assess if the same dose could be utilized in pts with lymphoma.
  • Pts with relapsed/refractory non-Hodgkin lymphoma (NHL) or Hodgkin's disease (HD) with evaluable disease and acceptable organ functions were eligible.
  • Dose limiting toxicity (DLT) assessed in cycle 1 included: related non-hem grade (gr) 3/4 tox; gr 4 neutropenia > 5 d or with fever > 100.5 °F; gr 4 thrombocytopenia > 7 d.
  • Diagnoses include mantle cell lymphoma (MCL; 4 pts), HD (3 pts), other NHL (2 pts).
  • Non-hem gr 3 events (no gr 4 noted): diarrhea (1 pt each in cohorts A and B, both in cycle 2), fatigue, anorexia, and leg DVT (each in 1 pt; all after cycle 1).
  • In 6 pts evaluable for efficacy, stable disease have been noted in 5 pts for 3 to +7 cycles, including 3 of 3 pts (one refractory) with MCL and 2 of 2 pts (both refractory) with HD.
  • Tumor shrinkage of 43 to 49% have been found in 1 HD and 2 MCL pts after cycle 2.
  • CONCLUSIONS: Oral Bel can be delivered safely with a d 1-14, q3w schedule in pts with lymphoma at a daily dose higher than what has been established for pts with solid tumors.
  • No protocol defined DLTs have yet been encountered in the dose range 750 to 1250 mg QD in pts with lymphoma.
  • Final evaluation will include additional pts and possible dose escalation.
  • The safety profile and early tumor shrinkage noted in MCL and HD warrants continued evaluation of Bel, especially in combination with other active compounds.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962263.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Boyle H, You B, Fronton L, Ribba B, Girard P, Tranchand B, Tod M, Coquelin H, Droz J, Flechon A: Major prognostic value of modeled AUC&lt;sub&gt;hCG-AFP&lt;/sub&gt;, a dynamic kinetic marker characterizing tumor marker decline of nonseminomatous germ cell tumors (NSGCT) intermediate-poor-risk patients according to the IGCCCG. J Clin Oncol; 2009 May 20;27(15_suppl):5085

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This may be due to the inaccuracy of methods employed so far, simplifying complex exponential decrease curves by a median half-life (HL).
  • AUC<sub>hCG-AFP</sub> was a significant prognostic factor in the univariate analysis on the 2 year PFS (100% vs 73.8% vs 67.7%, p = 0.035) as well as IGCCCG score (poor/intermediate risk groups), primary site (mediastinal/other) and HL<sub>hCG-AFP</sub>.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964275.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Brell JM, Hardacre J, Schulak J, Onders R, Stellato T, Sanabria J, Schulchter M, Strickland L, Sprosty R, Pink J: Characterization of human skeletal muscle in weight-losing pancreatic cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):9571

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Caspase-3, pAkt, and urinary 3-methylhistidine (u3-MH) were assessed by Western blot and high-performance liquid chromatography.
  • Two hundred differentially over- and under-expressed genes were examined in group A for potential association with cachexia.
  • Baseline u3-MH (p=0.86) and FFM (p= 0.28) did not differ; baseline BMI was lower in group A (p=0.04).
  • In 65% patients, progressive disease was noted within median time of 3 months.
  • CONCLUSIONS: Muscle proteolysis in human PC skeletal muscle was not demonstrated, perhaps due to unmeasurable proteolysis or use of non-informative endpoints.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963662.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Eichstadt SL, Dahl GV, Fisher PG, Ford JM, Schiffman JD: Correlation of a family history of cancer with risk of relapse and death in pediatric cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):10029

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of a family history of cancer with risk of relapse and death in pediatric cancer patients.
  • In particular, patients with Hodgkin Disease (HD) and FHC (n = 12) were more likely to relapse (RR 1.79, 95% CI 1.19-2.72) and at increased risk of death (RR 1.72, 95% CI 1.18-2.53), compared to HD with negative FHC (n = 8).
  • Additionally, an increased risk of death was associated with HD and ALL patients with positive FHC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962589.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Kohrt HE, Advani R, Hoppe R, Rosenberg S, Horning S, Lee PP: Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus (EBV) antigens in patients with EBV-negative Hodgkin's disease. J Clin Oncol; 2009 May 20;27(15_suppl):8573

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus (EBV) antigens in patients with EBV-negative Hodgkin's disease.
  • : 8573 Background: Multiple translational efforts in HD are actively investigating augmentation of the anti-tumor immune response by stimulating cytotoxic T lymphocytes (CTL) against tumor-associated EBV antigens.
  • It has previously been believed that this therapeutic strategy and presence of EBV-specific CTLs are limited to EBV-positive HD.
  • Here, we challenge this belief by characterizing EBV-specific CTL responses in EBV-negative HD.
  • METHODS: Among 52 consecutive patients with EBV-negative HD, CTL responses to latent antigens (LMP2, LMP2a) and lytic antigens (BMLF, BRLF) were serially assessed at diagnosis, during chemotherapy, and throughout followup for 2 years by IFN-γ Elispot and flow cytometric tetramer analysis.
  • RESULTS: We detected weak EBV-specific responses to both lytic and latent antigens by IFN-γ Elispot among patients with EBV-negative HD.
  • Chemoradiotherapy was associated temporally with an initial decrease in LMP2A- and BMLF1-specific responses during the first 5-15 weeks of treatment, which subsequently became more robust 20-50 weeks after diagnosis, 2 to 4-fold greater compared to response at diagnosis.
  • CONCLUSIONS: We confirm evidence of EBV-specific CTLs in patients with EBV-negative HD and provide the first report of dynamic variance in this population during treatment, challenging prior belief that patients with HD remain immunodeficient following therapy and arguing that the clinical significance of EBV-specific immune responses in EBV-negative HD should be further investigated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961017.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Khodadad K, Karimi S, Esfahani Monfared Z: Correlation between expression of MCM6, a new proliferative marker, and treatment outcome in patients with Hodgkin's disease. J Clin Oncol; 2009 May 20;27(15_suppl):e19547

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between expression of MCM6, a new proliferative marker, and treatment outcome in patients with Hodgkin's disease.
  • We evaluated MCM6 expression in Hodgkin's disease (HD) patients in order to find any correlation between MCM6 expression and treatment outcome.
  • METHODS: Formalin-fixed paraffin-embedded lymph node specimens of 55 patients with HD treated with ABVD regimen (± radiotherapy) were assessed for MCM6 expression by IHC.
  • The percentage of nuclear positivity in RS and mononuclear Hodgkin cells was evaluated in each case.
  • Clinical data, response to treatment and relapse rates were obtained from patients' medical records.
  • The MCM6 mean expression between relapsed and non-relapsed groups was marginally significant (21% vs 29.4%, P=0.057).
  • CONCLUSIONS: Our study on a limited number of patients revealed MCM6 is not a strong predictor for treatment outcome in patients with HD.
  • Our findings can be possibly explained by early G1 arrest of tumor cells and the role of cytokine production in pathogenesis of HD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960972.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Gundrum JD, Go R, Kwong R: Cancer in the oldest old population in the United States: Current statistics and projections. J Clin Oncol; 2009 May 20;27(15_suppl):9553

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 10 leading cancers by incidence (both sexes and decreasing order) are colorectal (388.9), lung (287.7), breast (250), prostate (211.5), urinary bladder (162.5), non-Hodgkin lymphoma (110.9), leukemia (85.1), melanoma (65), renal (46.4), and uterine (40.2).
  • The incidences of melanoma, non-Hodgkin lymphoma, renal, and lung cancers are increasing, while those of leukemia, prostate, breast, and colorectal cancers are decreasing.
  • Cancer specific survival (CSS) has been increasing continuously since 1973 for melanoma, non-Hodgkin lymphoma, breast, colorectal, prostate, and urinary bladder cancers but decreasing in recent years for colorectal, breast, prostate, and uterine cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963637.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Nabil IN Jr, Allam W, Alaoui K, Errihani H: Primary nasopharyngeal non Hodgkin lymphoma: A retrospective investigation of 26 patients. J Clin Oncol; 2009 May 20;27(15_suppl):e19552

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary nasopharyngeal non Hodgkin lymphoma: A retrospective investigation of 26 patients.
  • : e19552 Background: Primary nasopharyngeal non-Hodgkin lymphoma (NNHL) was uncommon.
  • In this retrospective study we report our experience dealing with this disease at the National Institute of Oncology.
  • METHODS: We retrospectively analyzed various characteristics of Primary NNHL: patient demographics, clinical and histological diagnosis, disease stage, treatment effects and outcome, in 26 patients treated at our institution between January 2001 and December 2007.
  • The major symptoms at first diagnosis were: nasal obstruction (88.6%), hypoacousia (88.4%), epistaxis (33.3%) and rhinorrhea (15.3%).
  • Clinical examination founded bilateral cervical lymph nodes in 17 cases (65%).
  • Histological analysis showed follicular lymphoma in 7 cases (26.9%), large B-cell lymphoma in 11 cases (42,3%) and T lymphoma in 4 cases ( 15,3%).
  • At the end of total treatment, 18 patients (69.2%) achieved complete response and remained disease free while 4 (15.4%) achieved partial response (>70%) and 4 (15.4%) were progressive (these patients received second line chemotherapy).
  • After 110 months median flow-up, median disease free and overall survival were not reached.
  • CONCLUSIONS: From our study and from the literature, we conclude that histological characteristics, principle of treatment and outcome of primary NNHL patients are similar to that of patients with nodal lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961093.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Gharib AF, Eltarhony SA, Elsawy WH: Soluble CD44 in patients with aggressive non-Hodgkin's lymphoma: Prognostic and clinical value. J Clin Oncol; 2009 May 20;27(15_suppl):e19539

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble CD44 in patients with aggressive non-Hodgkin's lymphoma: Prognostic and clinical value.
  • In this prospective study, we investigated the prognostic and clinical value of s-CD44 in patients with aggressive non-Hodgkin's lymphomas.
  • METHODS: s-CD44 concentration was measured in the sera of 64 patients with aggressive non-Hodgkin's lymphomas treated with standard CHOP by using chemiluminescence-enzyme immunoassay (EIA).
  • RESULTS: Circulating serum CD44 (s-CD44) levels have been found to change in parallel with response to therapy, but little is known about the predictive or prognostic significance of s-CD44.
  • Only 10 (31%) of the 32 patients with an International Prognostic Index (IPI) score 0 or 1 had s-CD44 concentration higher than the median level, whereas 11 (52%) of 21 patients with an IPI score ≥2 had a concentration higher than the median before initiation of treatment (P < .0001).
  • CONCLUSIONS: Our results showed that a high s-CD44 level before treatment is associated with a high IPI score, poor response to treatment, and unfavorable prognosis in aggressive non-Hodgkin's lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961002.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Pourtsidis AG, Doganis D, Baka M, Bouhoutsou D, Varvoutsi M, Servitzoglou M, Kosmidis S, Synodinou M, Strantzia C, Kosmidis H: Successful treatment with minimal chemotherapy followed by low-dose involved field radiotherapy in children with Hodgkin's disease: A 20-year experience in a single institution in Greece. J Clin Oncol; 2009 May 20;27(15_suppl):10052

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment with minimal chemotherapy followed by low-dose involved field radiotherapy in children with Hodgkin's disease: A 20-year experience in a single institution in Greece.
  • : 10052 Background: The vast majority of children with Hodgkin's disease (HD) nowadays have an excellent chance of definite cure.
  • The high curative rates as well as the prevention of late effects have to be among aims when managing children with HD.
  • The purpose of our retrospective study was to report the outcome and prognostic factors of patients (pts) less than 15 years of age with HD treated with chemotherapy (CT) followed by low dose radiation from 1987 to 2006.
  • Among 35 boys and 23 girls, age at diagnosis 4.5 - 15 years (median 12), all aged 7 years or less were boys (8/58).
  • Nodurar sclerosis was the predominant histology subtype (69%) and 45% had advanced disease (stages III or IV).
  • According the study period pts with early stage received 4 cycles of ABVD or VBVP and those with advanced stage disease alternating 3 cycles of MOPP/ABVD or 2 of MOPP/ABVP for stage III and alternating 3 cycles of MOPP/ABVD or 2 OPPA plus 4 COPP for stage IV.
  • All received salvage treatment in combination with high dose CT and autologous stem-cell transplantation (SCT).
  • Of the 5 relapsed all live 21 - 207 months (median 75 mo) from the dx of relapse and 41 - 232 mo (median 99) from the dx of disease.
  • CONCLUSIONS: In conclusion combined-modality therapy remains the standard of care for children with HD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962448.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Fan AC, Orban MW, Shirer AE, Rajwanshi R, Kong C, Natkunam Y, Lee HE, Coutre S, Felsher DW: Nanoscale analysis of changes in signaling proteins in patients treated with single agent atorvastatin for low-grade or refractory NHL. J Clin Oncol; 2009 May 20;27(15_suppl):11011

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 11011 Background: In preclinical studies using our transgenic lymphoma model, lymphoma regression upon atorvastatin treatment was associated with increased apoptosis and changes in phosphorylation of key signaling pathways including MAPK and STAT.
  • To determine if statins affect tumor signaling in patients, we designed a single arm phase II study, "Atorvastatin in Patients with Low Grade or Refractory Non-Hodgkin's Lymphoma."
  • To characterize changes in protein profiles, we have developed the use of a novel nano-immunoassay system (NIA) to simultaneously measure both phosphorylated and unphosphorylated protein isoforms.
  • Finally, changes in signaling associated with atorvastatin are cell specific: effects on tumor cells were distinct from effects on non-tumor T cells and monocytes.
  • CONCLUSIONS: Single agent atorvastatin has a measurable effect on tumor bioactivity in patients with lymphoma.
  • NIA and multi-color phosphoFACS can be used to monitor changes in cell signaling in very small clinical samples during therapeutic interventions.
  • Determining whether specific signaling molecules may be a biomarker for identifying lymphoma patients that respond to atorvastatin is worthy of further investigation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963976.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Skarin AT, Vekeman F, Laliberté F, Afonja O, Lafeuille M, Barghout V, Duh MS: Pattern of utilization of pegfilgrastim in patients with chemotherapy-induced neutropenia: A retrospective analysis of administrative claims data. J Clin Oncol; 2009 May 20;27(15_suppl):9624

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients who had a cancer diagnosis and chemotherapy within 120 days of their first pegfilgrastim injection were identified.
  • Analysis was also stratified by cancer type [Non-Hodgkin's lymphoma (NHL), lung, breast].
  • Further research is being conducted to assess the related clinical and economic impact of this pattern of usage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963900.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Tan H, Tomic K, Daniel G, Hurley D, Barron R: Evaluating risk of hospitalization with G-CSF use in real-world oncology practice. J Clin Oncol; 2009 May 20;27(15_suppl):6626

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluating risk of hospitalization with G-CSF use in real-world oncology practice.
  • This study examines prophylactic vs. delayed use of G-CSF and compares the effectiveness of prophylaxis with filgrastim (FIL) vs. pegfilgrastim (PEG).
  • METHODS: A retrospective analysis of administrative claims from U.S. commercial health plans identified adult patients with non-Hodgkin's lymphoma, breast, or lung cancer, treated with chemotherapy between July 2004 and January 2008.
  • For these patients, the first course of chemotherapy and each unique cycle with use of G-CSF (FIL or PEG) was identified and designated 'prophylaxis' if used within the first 5 days of each cycle, or 'delayed', if after day 5.
  • A generalized estimating equation (GEE) was used to adjust for baseline demographics and clinical characteristics.
  • Among prophylactic use in real-world oncology practice, PEG was associated with about a two-thirds lower risk of neutropenic hospitalization compared with FIL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961802.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Yoon D, Sohn B, Kim J, Yoo C, Kim S, Lee D, Kim S, Huh J, Lee J, Suh C: The role of prophylactic antimicrobials during autologous stem cell transplantation: A single center experience. J Clin Oncol; 2009 May 20;27(15_suppl):7105

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 7105 Background: The aim of this retrospective study was to investigate the efficacy of antibiotic prophylaxis during autologous peripheral stem cell transplantation (ASCT) in patients with multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961647.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Braun E, Katz D, Venugopal P, Larson M, Shammo J, Fung H, Gregory S: Safety analysis of radioimmunotherapy (RIT) in patients with relapsed or refractory low grade, follicular or transformed non-Hodgkin's lymphoma and mantle cell lymphoma based on age at time of therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e19529

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety analysis of radioimmunotherapy (RIT) in patients with relapsed or refractory low grade, follicular or transformed non-Hodgkin's lymphoma and mantle cell lymphoma based on age at time of therapy.
  • : e19529 Background: Radioimmunotherapy is a therapeutic option for relapsed or refractory indolent, follicular and transformed non Hodgkin's lymphoma and mantle cell lymphoma.
  • Groups characteristics such as sex, type of RIT, presence of disease in bone marrow, FLIPI/IPI and use of G-CSF were noted.
  • CONCLUSIONS: RIT should be considered a safe therapeutic modality in patients with refractory or relapsed indolent, follicular, NHL, transformed and Mantle Cell lymphoma regardless of age.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960911.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Amireault C, Camden S, Poulin J, Lemieux J: Evaluation of factors associated with recruitment in hematological clinical trials: A retrospective study. J Clin Oncol; 2009 May 20;27(15_suppl):6567

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of factors associated with recruitment in hematological clinical trials: A retrospective study.
  • : 6567 Background: Recruitment of patients in cancer clinical trials has been reported to be between 3%-5%.
  • METHODS: The objective was to measure the recruitment and its associated characteristics in hematology clinical trials for malignant diseases.
  • Clinical trials opened between 2002 and 2008 were selected.
  • For each protocol, main criteria were used to define the population under study (e.g., stage IV Hodgkin lymphomas first-line).
  • The study population filling the main criteria of a protocol included 195 observations in 17 protocols (186 different patients).
  • However, theses rates reached 68.2 % (61.2-75.1) and 23.1 % (17.9-29.8), respectively, among patients meeting the main criteria of a protocol (195 observations).
  • Patients reasons for refusals were (could have more than one reason): 50% unknown, 26.5% fear of side effects, 20.6% too many visits, 14.7 % already enough anxious about disease, other.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963805.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Fuh FK, Fuji R, Poon KA, Manning W Jr, Berry KK, Ramakrishnan V, Polson A, Ebens A, Prabhu S, Williams M: Pharmacodynamic effects of administration of maytansine conjugated anti-CD22 monoclonal antibodies to cynomolgus monkeys. J Clin Oncol; 2009 May 20;27(15_suppl):3051

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 3051 Antibody-based B-cell specific therapeutic approaches have revolutionized the treatment of non-Hodgkin's lymphomas (NHL) as well as other hematological malignancies.
  • However, a large variability in clinical response has been observed, and the need to develop effective new treatments remains urgent.
  • CMC-544, an antibody to a B-cell specific glycoprotein CD22 conjugated to the cytotoxin calicheamicin, has shown clinical activity in patients.
  • In addition, antibodies directed to B-cell targets such as rituximab and epratuzumab are in clinical trials for the treatment of NHL and autoimmune disorders.
  • B-cells and B-cell subsets were depleted in peripheral blood and lymphoid tissue (spleen, bone marrow) at all doses, with no apparent dose-dependent effects or substantial safety limitations.
  • Based on the nonclinical data, 10F4v3-DM1 exhibits an encouraging pharmacodynamic profile for the potential treatment of non-Hodgkin's lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961983.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Sola CB, Silva L, Saliba R, De Lima M, Giralt S, Qazilbash M, Champlin R, Khouri I, Popat U, Hosing C: Outcomes of autologous bone marrow transplantation in non-Hodgkin's lymphoma patients who failed peripheral blood stem cell mobilization. J Clin Oncol; 2009 May 20;27(15_suppl):7040

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of autologous bone marrow transplantation in non-Hodgkin's lymphoma patients who failed peripheral blood stem cell mobilization.
  • : 7040 Background: Patients (pts) with relapsed/refractory non-Hodgkin's lymphoma (NHL) who fail to mobilize adequate peripheral blood stem cells (PBSC) often undergo bone marrow (BM) harvest for autologous transplantation.
  • METHODS: In this retrospective study (May 1996-September 2006), we identified 36 out of a total of 750 pts with advanced NHL, who failed to collect adequate PBSC and subsequently underwent BM harvest followed by ABMT.
  • Twelve pts (35%) had history of BM involvement with lymphoma.
  • At the time of stem cell mobilization 18 (50%) were in complete remission (CR), 13 (37%) were in partial remission (PR) and 5 (13%) had progressive disease (PD).
  • RESULTS: The median total nucleated cell dose and CD34+ cell dose harvested/kg were 3.72 x 10<sup>8</sup> (range 0.25-58.0) and 1.6 x 10<sup>6</sup> (range 0.03-5.8), respectively.
  • Causes of death were: disease progression/relapse in 15 (60%), secondary malignancy in 3 (12%), multiorgan failure in 5 (20%), and unknown in 2 (8%).
  • Non-myeloablative allogeneic transplantation may provide better outcomes with similar toxicity and needs to be further studied.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961403.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Fowler NH, McLaughlin P, Kwak L, Hagemeister F, Fanale M, Fayad L, Pro B, Samaniego F: Lenalidomide and rituximab for untreated indolent non-Hodgkin's lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8548

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lenalidomide and rituximab for untreated indolent non-Hodgkin's lymphoma.
  • : 8548 Background: Despite advances in therapy and a better understanding of the natural history of indolent non-Hodgkins lymphomas (NHL), the optimal treatment for newly diagnosed patients (pts) has not been determined.
  • METHODS: Pts with indolent NHL who were previously untreated, with measurable disease (>1.5 cm), were eligible for enrollment.
  • Response was assessed after 3 cycles and at the end of therapy using the International Working Group Response Criteria.
  • In the 5 pts eligible for response assessment, 4 pts (80%) attained a complete response (CR), 1 patient (20%) had stable disease (SD).
  • After 3 cycles, one patient had unconfirmed stable disease who also was previously treated with combination chemotherapy for Hodgkin's lymphoma.
  • CONCLUSIONS: The combination of lenalidomide and rituximab has activity and is well tolerated with minimal toxicity in patients with newly diagnosed indolent lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960963.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Ngeow JY, Quek R, Tao M, Tan HC, Lim L, Tan I, Kaneswaran R, Lim ST: Analysis of long-term treatment outcomes and toxicty of HL. J Clin Oncol; 2009 May 20;27(15_suppl):e19536

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of long-term treatment outcomes and toxicty of HL.
  • : e19536 Background: Prognosis of patients with Hodgkin lymphoma (HL) has substantially improved but therapy of HL can however contribute to delayed toxicity.
  • Long term treatment outcomes of HL in our local population were evaluated.
  • METHODS: Clinical and treatment data was prospectively collected from all patients with a histological diagnosis of HL.
  • Patients who were young (< 30 years) were more likely to present with nodular sclerosis HL (p=0.0001).
  • 5 year OS for early stage HL was 92% and 88% for advanced stage HL.
  • Of note, comparing patients with early stage (Stage I/ II) HL (n=114) who had ABVD 4 cycles followed by involved field radiotherapy (IFRT) with those who received 6-8 cycles of ABVD, there was no difference in OS, FFTF (p= 0.99, 0.48 respectively).
  • Bulky early stage HL who received 6 cycles of ABVD and IFRT had better FFTF rates than those who had just 4 cycles of ABVD followed by IFRT (p=0.06).
  • In contrast, patients patients with advanced HL (Stage III/ IV) (n=70) who completed 6-8 cycles of ABVD did not benefit from additional IFRT even in the presence of bulky disease (n=15).
  • 1) Epidemiology of HL in Singapore is increasingly similar to that of developed countries with a peak in young adults.
  • 2)Young age was predictive of a nodular sclerosis subtype 3) Abbreviated chemotherapy using 4 cycles of ABVD followed by IFRT performed similarly to 6 cycles of ABVD in early stage HL, but in patients with bulky disease this may not be sufficient.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961005.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Gerrard M, Waxman I, Sposto R, Auperin A, Harrison L, Pinkerton R, Perkins SL, McCarthy K, Raphael M, Patte C, Cairo MS, FAB/LMB 96 Trial: Association of primary mediastinal B-cell lymphoma (PMBL) in children (C) and adolescents (A) with a significantly inferior prognosis: Final results of the FAB/LMB 96 trial. J Clin Oncol; 2009 May 20;27(15_suppl):10001

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of primary mediastinal B-cell lymphoma (PMBL) in children (C) and adolescents (A) with a significantly inferior prognosis: Final results of the FAB/LMB 96 trial.
  • : 10001 Background: Single pediatric cooperative group studies have demonstrated an EFS ranging from 65 - 75% in C & A with large cell lymphomas arising in the mediastinum (Lones/Cairo et al, J Clin Oncol, 2000; Burkhardt/Reiter et al, Br J Haematol, 2005; Seidman/Reiter et al, J Clin Oncol, 2003).
  • Recently, Staudt and Shipp have independently demonstrated that following gene expression profiling by oligonucleotide microarray that PMBL resembles more like classical Hodgkin lymphoma than diffuse large B-cell lymphoma with enhanced NF-κB pathway gene expression (Rosenwald et al, J Exp Med, 2003; Abramson et al, Blood, 2005).
  • RESULTS: There were 528 patients with stage III/IV disease treated on group B therapy on FAB/LMB 96 resulting in a 2 yr EFS of 84% (CI<sub>95</sub>: 82-86%).
  • 5 yr EFS was significantly inferior compared to the remainder of the other patients with stage III disease treated on group B therapy (54%: CI<sub>95</sub> 38-68% vs 85%: CI<sub>95</sub> 81-88%) (p < 0.001).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962546.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Guix B, Bartrina J, Tello J, Quinzanos L, Lacorte T: Dose escalation by high-dose 3D-conformal radiotherapy (HD-3D-CRT) or low-dose 3D-conformal radiotherapy plus HDR brachytherapy (LD-3D-CRT+HDR-B) for intermediate- or high-risk prostate cancer: Early results of a prospective comparative trial. J Clin Oncol; 2009 May 20;27(15_suppl):5118

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose escalation by high-dose 3D-conformal radiotherapy (HD-3D-CRT) or low-dose 3D-conformal radiotherapy plus HDR brachytherapy (LD-3D-CRT+HDR-B) for intermediate- or high-risk prostate cancer: Early results of a prospective comparative trial.
  • : 5118 Background: To report early and late toxicity and preliminary biochemical outcome in 445 patients with intermediate- or high-risk clinically localized prostate cancer treated with either HD-3D-CRT or with LD-3D-CRT+HDR-B.
  • Pts were assigned to one of the two treatment groups: 76 Gy HD-3D-CRT to the prostate in 38 fractions (group 1; 223 patients) or 46 Gy LD-3D-CRT+ 16 Gy HDR-B given in 2 fractions of 8 Gy (group 2, 222 patients).
  • CONCLUSIONS: High-dose 3D-EBRT +HDR brachytherapy is a safe and effective method of escalating the dose to the prostate without increasing the risk of late effects.
  • Acute and late rectal and urinary complications were significantly reduced with the combined treatment, compared with what was observed with high-dose conventional, 3D-CRT.
  • Short-term PSA control rates tends to be better with in the HDR-boosted patients as spected by higher effective-dose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964387.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Ghavamzadeh A, Allahyari A, Alimoghaddam K, Karimi A, Shamshiri A, Abolhasani R, Manookian A, Asadi M, Khatami F: Outpatient versus inpatient autologous stem cell transplantation for malignant hematologic disorders. J Clin Oncol; 2009 May 20;27(15_suppl):7042

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outpatient versus inpatient autologous stem cell transplantation for malignant hematologic disorders.
  • : 7042 Background: High-dose chemotherapy with autologous stem cell support is utilized for the treatment of a variety of malignancies including Hodgkin/non-Hodgkins lymphoma and acute leukemias.
  • METHODS: 9 outpatients (5 HL, 2 NHL, and 2 AML) were compared with 32 inpatients (15 HL, 8 NHL, and 9 AML; for whom the outpatient facilities were not ready) from May 2008 to December 2008.
  • They received conditioning regimen (CEAM for NHL and HL, busulfan and etoposide for AML) and stem cell infusion in hospital.
  • The day after SCT, outpatient group were discharged and followed by outpatient SCT team, and to be re-hospitalized in case of febrile neutropenia, after sepsis workup and performing chest x-ray, they were received the first dose of antibiotic in hospital and treatment continued in home.
  • CONCLUSIONS: Results show that out-patient autologous SCT in malignant hematologic disorders is feasible and comparable with inpatient protocol.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961405.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. O'Brien MM, Donaldson SS, Whittemore AS, Link MP: Second malignant neoplasms among survivors of pediatric Hodgkin disease treated with low-dose radiation (15-25.5 Gy) and chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):10003

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignant neoplasms among survivors of pediatric Hodgkin disease treated with low-dose radiation (15-25.5 Gy) and chemotherapy.
  • : 10003 Background: Second malignant neoplasms (SMN) are a known complication of Hodgkin disease (HD) treatment.
  • While it is theorized that lower radiation doses may be associated with lower SMN risk, long-term follow-up of children treated with low-dose radiation is lacking.
  • We report the occurrence of SMN among pediatric HD survivors treated at Stanford with chemotherapy and low-dose radiation from 1970 to 1990.
  • Fifteen patients developed 17 secondary solid tumors (5 thyroid carcinomas, 6 breast carcinomas, 4 sarcomas, 1 bladder paraganglioma, 1 melanoma) at a median of 15.4 years.
  • All solid tumors except the melanoma occurred within or at the margin of radiation fields, ranging in dose from 15-26.5 Gy.
  • Cumulative incidence of any SMN is 17% (95%CI 10.5-26.7) at 20 years following HD diagnosis.
  • In univariate analysis, older age at HD diagnosis (>11 years) and female gender were associated with SMN (p<0.05).
  • CONCLUSIONS: The incidence of SMN in pediatric HD survivors is elevated following treatment with chemotherapy and low-dose radiation.
  • Sarcomas, breast, and thyroid carcinomas occurred with similar frequency and latency as found in studies of HD survivors who received high-dose radiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962547.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Reategui RD, Beltran B, Morales D, Vera L, Quinones P, Portugal K, Desposorio C, Capellino A, Castillo J: AIDS-related lymphoma (ARL): Efficacy of highly active anti retroviral therapy (HAART) on survival and prognostic factors in a general hospital in Peru. J Clin Oncol; 2009 May 20;27(15_suppl):e19545

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related lymphoma (ARL): Efficacy of highly active anti retroviral therapy (HAART) on survival and prognostic factors in a general hospital in Peru.
  • METHODS: The clinical records of 2,502 HIV-infected patients seen in our institution from March 1997 to March 2008 were reviewed.
  • RESULTS: Forty-eight patients with HIV-associated lymphoma were identified.
  • From the 48 ARL identified 44 were non Hodgkin lymphoma (NHL) and 4 were Hodgkin lymphoma.
  • From 42 systemic NHL: 38 (90,5%) were of B-cell and 4 (9,5%) were of T-cell.
  • Three groups of patients were included: 13 patients (31%) received HAART previous the diagnosis of ARL, 21 patients (50%) initiated HAART after ARL diagnosis and 8 patients (19%) did not receive HAART.
  • HAART treatment before the diagnosis of NHL increases the survival (54% versus 9,5% versus 25% respectively, p=0.048).
  • This group had a better survival rate than those who did not receive chemotherapy (50% versus 4,5%, p< 0.0001) The overall response to chemotherapy was 80% with CR (n=11, 55%), PR(n=5, 25%) and PD in four (20%).
  • In a multivariate analysis, IPI score > 2, presence of B symptoms and no HAART previous ARL diagnosis were statistically associated to worse survival with p-values of 0.0001, 0.018 and 0.048 respectively.
  • CONCLUSIONS: In our study the use of HAART is effective when started before ARL diagnosis.
  • IPI score > 2, B symptoms and no HAART previous the diagnosis were unfavorable prognostic factors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960996.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Masuda N, Ando M, Aogi K, Ino H, Iwata H, Tokuda Y, Nakamura S, Yamamoto N, Fujiwara Y: Randomized phase II study of neoadjuvant chemotherapy and trastuzumab for operable breast cancer with overexpression of HER2. J Clin Oncol; 2009 May 20;27(15_suppl):565

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 565 Background: Achievement of pathological complete response (pCR) by primary systemic therapy (PST) correlates with improved survival in operable breast cancer patients.
  • Based on data of the higher pCR rate with concomitant chemotherapy and trastuzumab (H) reported by some clinical trials, we performed a multi-center, prospective randomized phase II study to evaluate the efficacy of adding H to standard chemotherapy and to determine more effective agent which will show higher pCR by the comparison between weekly paclitaxel (P) and tri-weekly docetaxel (D) in neo-adjuvant setting for HER-2+ pts.
  • PST regimen was scheduled as the sequential chemotherapy with 4 cycles of CEF (cyclophosphamide, epirubicin 100 mg/m<sup>2</sup>, 5FU) followed by 4 cycles of q3w H with qw P 80 mg/m<sup>2</sup> (HP) or q3w D 75 mg/m<sup>2</sup> (HD).
  • RESULTS: From March 2007 to June 2008, 102 pts were enrolled and randomized as well balance in the same number, median age (51yo), and the same distribution of clinical stage.
  • Pre-matured data was available for 60 pts whom central review had been completed: there was no significantly difference in pCR rate between two groups, 53% (95%CI: 35.4-71.1%) on HP and 47% (28.8-64.5%) on HD.
  • CONCLUSIONS: In HER-2+ pts, PST with CEF followed by HP or HD might be equally active and achieving high pCR without significant toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960723.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Barron R, Michels SL, Reynolds MW, Tomic K, Yu J, Lyman G: Risk of mortality in patients with cancer experiencing febrile neutropenia. J Clin Oncol; 2009 May 20;27(15_suppl):9561

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The risk of mortality from FN is not well characterized in clinical practice.
  • METHODS: Patients with cancer receiving chemotherapy in clinical practice were identified from the HealthCore Integrated Research Database, a geographically diverse spectrum of fully adjudicated longitudinal claims data from 13 health plans with over 20 million US lives.
  • Patients experiencing FN were compared to propensity score-matched patients not experiencing FN within tumor types of Non-Hodgkin lymphoma (NHL), breast, lung, colorectal and ovarian cancer.
  • Prevention of FN is of high importance and should be carefully considered in clinical practice.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963629.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Lansigan F, Cooper D, Seropian S, Foss F: Autologous and allogeneic transplantation for aggressive T-cell lymphomas: A single institution experience. J Clin Oncol; 2009 May 20;27(15_suppl):8558

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous and allogeneic transplantation for aggressive T-cell lymphomas: A single institution experience.
  • : 8558 Aggressive T-cell lymphomas (ATCL) represent 10-15% of non-Hodgkin lymphoma and have a worse prognosis than aggressive B-cell lymphomas.
  • The Auto group consisted of 6 PTCLu, 12 ALCL (5 Alk+, 5 Alk-, 2 Alk unk), 4 AITL, 1 CTCL with transformation, and 1 T-lymphoblastic lymphoma.
  • Median time from diagnosis to Allo or Auto was 18 and 8mo, respectively.
  • The non-relapse mortality was 33%(Allo) and 8%(Auto).
  • Within the Auto group, 14(58%) were transplanted in first complete remission(CR1), and 10(42%) in CR2, beyond CR2, or PR.
  • Patients in CR1 had significantly better PFS (57 vs 17mo, p=0.007) and OS (76 vs 29mo, p=0.004) than those in CR2, beyond CR2, or PR.
  • For patients with resistant or relapsed disease, Allo should be strongly considered rather than Auto.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960993.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Flowers C, Sinha R, Kaufman J, Shenoy P, Lewis C, Bumpers K, Rogatko A: Bortezomib plus modified R-CHOP as initial therapy for indolent B-cell lymphomas: Phase I results. J Clin Oncol; 2009 May 20;27(15_suppl):8577

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib plus modified R-CHOP as initial therapy for indolent B-cell lymphomas: Phase I results.
  • : 8577 Background: Adding rituximab (R) to chemotherapy improves survival for patients (pts) with follicular lymphoma (FL) and other indolent non-Hodgkin lymphomas (NHL), but not all pts respond.
  • Bortezomib (B) + RCHOP has a high complete response (CR) rate, but higher doses of B with standard vincristine produced severe neuropathy.
  • The maximum tolerated dose (MTD) was defined as the regimen at which <30% grade ≥3 non-hematological or grade ≥4 hematological toxicity (>14 days) occurs.
  • Dose escalation used the Escalation with Overdose Control Bayesian method with upper bound (θ=0.3).
  • This facilitated MTD finding with fewer pts given prior data on B+RCHOP.
  • 6 pts (55%) had stage IV disease; 8 (64%) had FLIPI ≥2.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962274.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Paoluzzi L, Scotto L, Seshan VE, O'Connor OA: Evaluation of the potential of histone deacetylase inhibitors to synergize the antineoplastic effects of the proteasome inhibitor bortezomib in mantle cell lymphoma (MCL). J Clin Oncol; 2009 May 20;27(15_suppl):8584

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the potential of histone deacetylase inhibitors to synergize the antineoplastic effects of the proteasome inhibitor bortezomib in mantle cell lymphoma (MCL).
  • HDACIs are known to induce cell death in malignant cells through multiple mechanisms, including up-regulation of death receptors, disruption of Hsp90 function and generation of reactive oxygen species.
  • Mantle cell lymphoma is an aggressive subtype of non-Hodgkin lymphoma characterized by the reciprocal translocation t(11;14)(q13;q32) leading to the overexpression of cyclin D1.
  • METHODS: We investigated the cytotoxicity of romidepsin and belinostat alone and in combination with the proteasome inhibitor bortezomib in cell lines of mantle cell lymphoma (HBL2, Granta519, Jeko1).
  • RESULTS: The IC<sub>50</sub> values for R and B alone at 24 hours were: HBL-2: R=4.7nM, B=490nM; Jeko-1: R=3nM, B=750nM; Granta519: R=45nM, B=30,700nM.
  • The combination of belinostat (100-1000nM) or romidepsin (1-40nM) with bortezomib (3-4nM) showed synergism in all cell lines at different concentrations.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962269.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Cadoo KA, Lowery MA, Cumiskey J, McCaffrey J, Carney DN: Long term follow-up of primary B and T cell non-Hodgkin's lymphoma (NHL) of the gastrointestinal (GI) tract. J Clin Oncol; 2009 May 20;27(15_suppl):e19516

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long term follow-up of primary B and T cell non-Hodgkin's lymphoma (NHL) of the gastrointestinal (GI) tract.
  • : e19516 Background: Anthracycline based chemotherapy is the treatment of choice for aggressive primary lymphomas of the GI tract, with surgery reserved for management of complications.
  • Median age at diagnosis was 60 (15-83).
  • Of the aggressive lymphomas (63), all patients with T cell lymphoma had small bowel as primary site and histological evidence of celiac associated enteropathy, even in the absence of known celiac disease.
  • 39 (62%) patients underwent surgery at diagnosis due to acute presentation with perforation, bleeding or obstruction, or to obtain histology.
  • Following confirmed diagnosis, 61 patients received anthracycline based chemotherapy.
  • 2 patients with T cell lymphoma presented with perforation, were treated with surgery only and died of rapid disease progression.
  • Of the 63 patients with aggressive NHL, 37 (59%) remain alive & disease free at median follow up of 13 years (1-24).
  • 35 (67%) patients with DLBCL are alive & disease free.
  • Only 2 (18%) of the T cell lymphomas are alive & disease free.
  • All deaths in the T cell group were due to progressive disease.
  • However, in contrast, coeliac enteropathy associated T-cell lymphomas present with rapidly progressive disease & have a survival of < 20% with chemotherapy and/or surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960953.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Muslimani A, Spiro T, Chaudhry A, Taylor H, Jaiyesimi I, Elson P, Daw H: Value of International Prognostic Score (IPS) in predicting need for bone marrow biopsy (BMB) in Hodgkin's lymphoma (HL). J Clin Oncol; 2009 May 20;27(15_suppl):e19531

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of International Prognostic Score (IPS) in predicting need for bone marrow biopsy (BMB) in Hodgkin's lymphoma (HL).
  • : e19531 Background: BMB is frequently performed during the staging of patients (pts) with HL.
  • The Ann Arbor classification is currently used to detect pts requiring BMB.
  • METHODS: We retrospectively reviewed charts of 1215 histologically proven HL pts from Jan 2000-Dec 2008 at Cleveland Clinic Taussig and Fairview Moll Cancer Centers.
  • BMI by histology was 4% lymphocyte-rich, 5% nodular sclerosis, 20% mixed-cellularity and 21% lymphocyte-depleted.
  • CONCLUSIONS: using an IPS of >3 for predicting BMI in HL doubled the spec associated with Ann Arbor classification with little loss of sen.
  • The implementation of IPS is a practical and reliable tool that will allow physicians to predict BMI in HL pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961027.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Hensel M, Goetzenich A, Hanhoff N, Wolf E, Knechten H, Mosthaf F: Cancer incidence in HIV-positive patients in Germany: A nation-wide survey from 2000 to 2007. J Clin Oncol; 2009 May 20;27(15_suppl):e22115

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to gather data on the epidemiology of AIDS-defining (AD) and non-AIDS-defining (NAD) malignancies in HIV-positive patients (pts) in Germany in the past decade.
  • The questionnaire requested information on all malignancies in HIV-positive pts, tumor stage, CDC (Center for Disease Control)-stage of the HIV infection, sex, treatment and clinical course.
  • The majority of pts had advanced HIV-disease (CDC stage C3), but the proportion of pts with stage C3 decreased from 58% in 2000 to 36.8% in 2007.
  • 253 (45.8%) were AD as follows: 132 Kaposi Sarcomas, 109 aggressive B-cell lymphomas, 12 invasive cervix carcinomas.
  • The B-cell lymphomas further included 28 Burkitt's lymphomas, 30 DLBCL, 9 Castleman diseases, 8 primary cerebral lymphomas.
  • Among the 299 cases (54.2%) of NAD malignomas were 213 solid tumors including 71 anal carcinomas (= 33.5% of all NAD malignancies) and 85 hemoblastoses including 29 Hodgkin lymphomas (= 9.6% of all NAD malignancies).
  • Interestingly, only 1 of 8 primary cerebral lymphomas has been reported after 2001.
  • The number of pts with Hodgkin's lymphoma has increased constantly from 2000 to 2007.
  • Anal carcinomas and Hodgkin's lymphomas in particular were markedly more prevalent in our HIV-positive cohort compared to published reports of the general population.
  • The incidence of primary cerebral lymphomas seems to decrease, whereas the incidence of Hodgkin's lymphoma is increasing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963512.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Eckardt JR, Ku N, DeMaggio A, Reese M, Levonyak M, Jain V: Impact of direct physician-to-physician contact on accelerating oncology clinical trial accrual. J Clin Oncol; 2009 May 20;27(15_suppl):6613

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of direct physician-to-physician contact on accelerating oncology clinical trial accrual.
  • : 6613 Background: The development of more effective oncology agents is critically dependent on the completion of clinical trials; currently, >4000 oncology trials listed in www.clinicaltrials.gov are accruing pts in the US.
  • Unfortunately, only 3-5% of new cancer pts participate in clinical trials and most trials do not meet their projected accrual timelines.
  • Barriers to pt accrual include physician awareness & attitudes, access to protocols, administrative burdens to conduct clinical trials, cost to physicians and pts, and pt concerns about participation in research trials.
  • To overcome at least some of these barriers, we investigated a strategy to improve clinical trial accrual that optimizes trial placement and awareness through a direct physician to physician intervention.
  • METHODS: For each site, a customized enrollment plan is established after initial assessment of interest and accrual potential.
  • Implementation of the enrollment plan includes clinical communications and medical support delivered through direct physician to physician interactions.
  • From Feb 2008 to December 2008, we implemented this strategy to increase accrual to 5 oncology trials (2 placebo controlled randomized trials and 3 phase II trials in breast cancer, non-Hodgkin's lymphoma and soft tissue sarcoma).
  • CONCLUSIONS: The use of our current model of optimizing trial placement and awareness through a direct physician to physician intervention has been successful in significantly accelerating clinical trial accrual in 5/5 trials initiated to date.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961766.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Azria D, Gligorov J: Prevalence and management of oropharyngeal candidiasis in cancer patients: Results of a prospective French multicentric survey. J Clin Oncol; 2009 May 20;27(15_suppl):e20590

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and management of oropharyngeal candidiasis in cancer patients: Results of a prospective French multicentric survey.
  • International guidelines recommend the use of broad spectrum local antifungal agents as first line treatment using old published data.
  • METHODS: Candidoscope concerned patients suffering from solid tumors or non-Hodgkin's lymphoma (NHL) and still under treatments.
  • Breast cancer population was the most frequent disease presenting untreated OPC (n= 47, 24%).
  • The most common clinical presentation for OPC was the erythematous form (62%).
  • CONCLUSIONS: The prevalence of OPC in treated cancer patients is frequent with important clinical consequences.
  • Systemic treatment compliance delivered according to the international guidelines is often poor and are strongly improved by the use of daily MBT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961172.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Vigil CE, Ayala E, Sokol L: Autologous stem cell transplant in peripheral T cell lymphomas: Single institution 10-year retrospective analysis. J Clin Oncol; 2009 May 20;27(15_suppl):e19538

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplant in peripheral T cell lymphomas: Single institution 10-year retrospective analysis.
  • : e19538 Background: Peripheral T-cell lymphoma is a rare entitydisease, compromising 10% of non-Hodgkin's lymphoma worldwide and 5% of all lymphoid neoplasms in the United States.
  • High-dose chemotherapy followed by autologous haematopoietic stem cell transplantation, has been explored in recent years with little experiences.
  • METHODS: A retrospective analysis on patients with diagnosis of peripheral T-cell lymphoma receiving autologous stem cell transplant was conducted (January 1997 to July 2008).
  • The patients were stratified according to their International Prognostic Index (IPI), disease status at the time of transplant and histology type.
  • RESULTS: Twenty-nine subjects were identified, with a median age of 51; 13 patients had Anaplastic T cell, 18 patient had PTCL-nos, and 6 patients with angioimmunoblastic T cell lymphoma.
  • Seventeen patients (58.62%) presented with an aa IPI score greater than 2.4 patients were in complete remission, 15 at first relapse, 4 in greater than 1 episode, and 6 with refractory disease at the time of transplantion.Kaplan Meier overall survival (OS) 72 and relapse free survival (RFS) was 62 at 1 year respectively.
  • A multivariate analysis and new risk stratification based on the IPI score system and disease status at time of transplant were employed.
  • CONCLUSIONS: The status at time of transplant with new methods for evaluation of minimal residual disease may help in assessing outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961010.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G, Kaplan H, Voralia M, Pietronigro D, Vose JM: Efficacy of lenalidomide oral monotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma: Final results of NHL-001. J Clin Oncol; 2009 May 20;27(15_suppl):8560

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of lenalidomide oral monotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma: Final results of NHL-001.
  • We conducted a phase II trial of single-agent lenalidomide in indolent non-Hodgkin's lymphoma (NHL).
  • Oral lenalidomide 25 mg was self-administered once-daily on days 1-21 of every 28-day cycle for up to 52 weeks as tolerated, or until disease progression.
  • Patients had received a median of 3 prior systemic therapies (1-17) and half of all patients were refractory to their last therapy.
  • Twenty-seven percent (6/22) of patients with follicular lymphoma grade 1 or 2, and 22% (4/18) of patients with small lymphocytic lymphoma responded to therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960983.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Matasar MJ, McCallen LN, Riedel ER, Ford JS, Oeffinger KC, Straus DJ: Late mortality and morbidity of patients with Hodgkin lymphoma treated in adulthood. J Clin Oncol; 2009 May 20;27(15_suppl):8547

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late mortality and morbidity of patients with Hodgkin lymphoma treated in adulthood.
  • : 8547 Background: Increased late mortality and morbidity have been observed among adult survivors of Hodgkin lymphoma (HL) treated in childhood, but are less well characterized for patients treated in adulthood.
  • The study population consisted of all patients treated on one of 6 consecutive first-line trials of combined modality therapy (CMT), one of which included a chemotherapy-only arm.
  • At time of survey, 227 patients (30.4%) had died: 107 deaths from HL, 100 from causes other than HL, and 20 from unknown cause ( Table 1 ).
  • Cumulative risk of death due to HL is surpassed by causes other than HL by 22 years post-treatment.
  • The most prevalent severe morbidities included second primary malignancy (SPM) (17%), cardiovascular (CV) (18%) and neurologic (18%) disease.
  • CONCLUSIONS: Among adults treated on trials of CMT, by 22y post-treatment the risk of death due to HL is surpassed by risk of death due to other causes.
  • Survivors of HL treated during adulthood experience substantial late morbidity.
  • These findings underscore the importance of efforts directed at prevention of and early intervention for late morbidity in adult survivors of HL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960964.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Kingsley E, Richards D, Garbo L, Gersh R, Robbins G, Leopold L, Brill J, Di Bella N: An open-label, multicenter, phase II study of AT-101 in combination with rituximab (R) in patients with untreated, grade 1-2, follicular non-Hodgkin's lymphoma (FL). J Clin Oncol; 2009 May 20;27(15_suppl):8582

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An open-label, multicenter, phase II study of AT-101 in combination with rituximab (R) in patients with untreated, grade 1-2, follicular non-Hodgkin's lymphoma (FL).
  • RESULTS: 23 pts enrolled: median age 64 yrs; FLIPI 0-5: 0%/17%/65%/13%/4%; Grade 1/2: 61%/39%; bulky disease (>5cm<sup>3</sup>): 35%; stage: 1-4 4%/4%/30%/61%; bone marrow + 48%.
  • The best ORR is at the upper limit of reported ORR for R alone; therefore a randomized trial is required to definitively determine activity of the combination.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962265.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Hassan MA, Sleem MM: Phase II trial comparing darbepoetin alfa every 3-week versus weekly epoetin alfa for the treatment of chemotherapy-induced anemia. J Clin Oncol; 2009 May 20;27(15_suppl):e20724

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Forty patients with a diagnosis of nonmyeloid malignancy with 8 weeks of planned chemotherapy, age 18 years, and anemia (hemoglobin 10 g/dL).
  • RESULTS: Forty patients with a diagnosis of nonmyeloid malignancy, the median age was 49 years and 52 years for DA and EA groups respectively, The majority of patients had solid tumors: Common cancer types for (DA - EA) groups were gastrointestinal (8 -5), breast (3-6), lung (3-3), soft tissue sarcoma (2-1), genitourinary (2-1), non-Hodgkin's lymphoma (1-1), multiple myeloma (1-1), Hodgkin's lymphoma (0-1), and metastatic with unknown primary in (1-0) respectively .

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962022.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Oatis WS, Nonzee N, Markossian T, Shankaran V, McKoy J, Evens A, Gordon L, Winter J, Calhoun E, Bennett CL: Interpreting out-of-pocket expenditures for cancer patients: The importance of considering baseline household income information. J Clin Oncol; 2009 May 20;27(15_suppl):6541

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report income-adjusted out-of-pocket cost ratios for 50 patients with lymphoma and 156 patients with breast cancer.
  • METHODS: Patients with lymphoma or breast cancer provided 3-month retrospective documentation of cancer-related out-of-pocket costs.
  • Direct non-medical costs are cancer-related peripheral costs, such as transportation and meals.
  • Mean monthly out-of-pocket costs for patients with lymphoma were slightly greater than for those with breast cancer ($1,888 vs $1,455, respectively).
  • Among patients with an annual income of $30,000 or less, the total monthly out-of-pocket costs were more than 3 times the monthly household income for patients with lymphoma and equal to the monthly household income for patients with breast cancer.
  • The total mean income-adjusted cost ratio was 1.75 for patients with aggressive non-Hodgkin lymphoma versus 0.42 and 0.61 for those with indolent non-Hodgkin lymphoma or Hodgkin disease, respectively.
  • CONCLUSIONS: Cancer-related out-of-pocket expenses disproportionately affect lower-income individuals with lymphoma or breast cancer and are primarily driven by the financial burden of co-payments for medical care.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964057.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Vera L, Reategui R, Beltran B, Morales D, Capellino A, Desposorio C, Castillo J: The clinicopathological spectrum of HIV-associated lymphoma: Eleven-year-experience in a general hospital in Peru. J Clin Oncol; 2009 May 20;27(15_suppl):e19561

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinicopathological spectrum of HIV-associated lymphoma: Eleven-year-experience in a general hospital in Peru.
  • : e19561 Background: The clinicopathological spectrum of HIV-associated lymphomas in developing countries has not been clearly defined.
  • METHODS: This is a retrospective review of the clinical records of patients with diagnosis of HIV in our institution from March 1997 to March 2008.
  • We reviewed 2502 clinical records.
  • RESULTS: Forty-eight patients with HIV-associated lymphoma were identified.
  • 32 patients (67%) had clinical stage III-IV, B symptoms 35 (73%), the International Prognostic Index was low-risk 20 patients (42%), low-intermediate risk 15 patients (31%), high-intermediate risk 10 patients (21%) and high-risk 3 patients (6%).
  • Forty-four cases (92%) were diagnosed with non-Hodgkin lymphoma (NHL) and 4 cases (8%) with Hodgkin lymphoma (HL).
  • From the 44 NHL cases, 40 cases (91%) were of B-cell origin; 23 cases (57.5%) had diffuse large B-cell, 9 cases (22.5%) had Burkitt, 3 cases (7.5%) had plasmablastic, 2 cases (5%) had primary CNS, 2 cases (5%) had MALT and 1 case (2.5%) had primary effusion lymphoma.
  • The remaining 4 cases (9%) were of T-cell origin; 3 cases (75%) had peripheral T-cell lymphoma NOS and 1 case (25%) was ALK-negative anaplastic large cell lymphoma.
  • Only 16 patients (33%) were receiving HAART previously the diagnosis of NHL and 33 patients (68%) received any oncology treatment.
  • Also a high proportion of T-cells lymphomas are found.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961062.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Schilling MB, Parks C, Deeter RG: Costs and outcomes associated with febrile neutropenia-related hospitalizations across patients with varying cancer types: A retrospective analysis. J Clin Oncol; 2009 May 20;27(15_suppl):e20560

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e20560 Background: Neutropenia, the major dose-limiting toxicity of chemotherapy, is a frequent, often serious, and sometimes fatal complication of myelosuppressive chemotherapy.
  • Its economic and clinical impact is often under-appreciated, and thus this study evaluates the contribution of febrile neutropenia (FN) by tumor type as related to healthcare cost and mortality.
  • METHODS: FN patients in this study were identified as having cancer (ICD-9-CM: 140.xx - 208.xx), neutropenia (288.0x) and either opportunistic infections (110 total codes) or fever of unknown origin (780.6) who were hospitalized between 1/05 and 6/08 in a retrospective cohort study from the Aspen US healthcare database (∼11 million pts, >342 inpatient facilities, and >300 million charge-detail records).
  • Unadjusted mean healthcare cost of hospitalization, length of hospital stay (LOS), and mortality rates were calculated, stratifying by cancer type (breast, metastatic breast, and lung cancers, non-Hodgkin lymphoma (NHL), or other hematologic tumors).
  • RESULTS: Among 598 hospitalized patients (mean age 63 years; 53% female) with cancer experiencing FN, the mean cost of hospitalization, LOS and mortality varied significantly by tumor type ( Table ).
  • The tumor type is important in assessing the economic and clinical impact of FN hospitalizations.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961149.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Henderson TO, Hlubocky F, Diller L, Daugherty C: Preferences and knowledge gaps among pediatric oncologists regarding the care of childhood cancer survivors: A survey of nearly 1,200 physicians. J Clin Oncol; 2009 May 20;27(15_suppl):6561

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A second mailing for non-responders is planned.
  • Choosing from closed-ended responses: 37% say they prefer to follow CCS as long as possible, 21% prefer for the patients to be followed by a physician other than themselves, and 29% are willing to follow them in the absence of a more suitable physician.
  • In a clinical vignette of 29 year old women exposed to mantle radiation and anthracyclines (150 mg/m2) for Hodgkin's lymphoma at 16 years of age: 30% of respondents did not appropriately recommend yearly breast cancer surveillance (based on Children's Oncology Group LTFU guidelines); 41% of respondents did not appropriately recommend cardiac surveillance; and 15% of respondents did not appropriately recommend yearly thyroid screening.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963799.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Indelicato DJ, Keole SR, Shahlaee AH, Morris CG, Gibbs CP, Scarborough MT, Islam S, Marcus RB: Ewing tumors of the chest wall: Local control and long-term outcomes. J Clin Oncol; 2009 May 20;27(15_suppl):e21501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e21501 Background: Primary sarcomas of the lungs and mediastinum are rare and few data are reported on treatment and results of therapy.
  • Pts characteristics: median age 41 (19-80 y), male/female 19/12; symptoms at diagnosis: dyspnoea (42%), chest and shoulder pain (39%), cough (35%), hemophtoae (13%), discomfort (10%).
  • 4 pts had a previous history of mediastinal radiation for Hodgkin's and non-Hodgkin's linfomas.
  • 5 mediastinal tumours were located as follows: 2 in anterior part, 1 in posterior and 2 in the middle (sarcomas of the heart).
  • 26 lung sarcomas presented as a singular mass in 23 cases and as a metastatic disease in 3.
  • RESULTS: In 20/31 cases the tumour was immediately resected (3 mediastinal masses and 17 lung sarcomas).
  • The histology were: peripheral nerve tumour 7, leiomyosarcoma 4, MFH 2, fibrosarcoma 2, liposarcoma 1, angiosarcoma 2, undifferentiated sarcoma 1, solitary fibrous tumour 2, rhabdomyosarcoma 2, synovialsarcoma 2, pulmonary artery sarcoma 1, pleuropolmonary blastoma 1, malignant hemangiopericytoma 1, mixoid chondrosarcoma 1, ectopic osteosarcoma 1, aggressive fibromatosis 1.
  • Only 4 pts received neoadjuvant chemotherapy, 11 adjuvant CT, 5 exclusive CT + RT for inoperable disease.
  • Local relapse or metastatic progression were recorded in 16/23 pts and 12 received one or more lines of palliative CT.
  • Of these only 8 are alive (2 with disease).
  • Volume of disease, complete resection and grading are the dominant prognostic factors.
  • CONCLUSIONS: Primary sarcomas of the lungs and mediastinum have a very severe prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963390.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Papadopoulos A, Vrettos I, Kamposioras K, Charitos D, Giannopoulos G, Pectasides D, Niakas D, Economopoulos T: Comparing health-related quality of life (HRQL) of cancer patients undergoing chemotherapy with family members in a tertiary hospital. J Clin Oncol; 2009 May 20;27(15_suppl):e20535

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The SF-36 health survey was used to evaluate and compare HRQL which contains eight scales measuring physical functioning (PF), role physical (RP), bodily pain (BP), general health perception (GH), vitality (VT), social functioning (SF), role emotional (RE), and mental health (MH), with higher scores (0-100 range) reflecting better-perceived health.
  • CONCLUSIONS: Although the physical health was significantly higher in the family members as it was expected for a healthy population, the mental health and especially MCS was significantly lower from the cancer patients undergoing chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960974.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Knop S, Liebisch P, Wandt H, Kropff M, Jung W, Kroeger N, Sezer O, Straka C, Fingerle-Rowson G, Einsele H: Bortezomib, IV cyclophosphamide, and dexamethasone (VelCD) as induction therapy in newly diagnosed multiple myeloma: Results of an interim analysis of the German DSMM Xia trial. J Clin Oncol; 2009 May 20;27(15_suppl):8516

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 8516 Background: Cytoreductive induction followed by HD-MEL and ASCT is considered standard of care for younger patients (pts) with multiple myeloma (MM).
  • The first 30 pts were included in the dose finding study to determine the optimum dose of IV C in conjunction with Vel and D.
  • Primary study objective is response rate (≥ PR) to VelCD according to the EBMT criteria.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960882.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Yi J, Kim S, Lee S, Park S, Ko Y, Choi J, Kim W: Clinical usefulness of PET/CT in initial staging and response evaluation of primary gastric lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):e19541

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical usefulness of PET/CT in initial staging and response evaluation of primary gastric lymphoma.
  • : e19541 Background: Positron emission tomography (PET)/computed tomography (CT) scan has a well-established role in the management of non-Hodgkin's lymphoma (NHL).
  • However, in case of the primary gastric lymphoma, which is the most frequent extranodal NHL, the role of PET/CT scan is still controversial.
  • METHODS: We retrospectively analyzed 42 patients with primary gastric lymphoma who underwent PET/CT scans; 32 patients with diffuse large B-cell lymphoma (DLBCL) and 10 patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) were analyzed.
  • After corresponding treatment, response was evaluated by conventional CT scans or PET/CT scans and endoscopy with biopsy Results: Nine patients were up-staged based on the results of their PET/CT scan compared to CT (7 DLBCL, 2 MALT lymphomas) while six patients were down-staged by the PET/CT scan.
  • Three patients with DLBCL, who showed an initially high SUVmax, died of disease progression.
  • All of these gastric lesions were grossly and pathologically benign lesions without evidence of lymphoma cells.
  • CONCLUSIONS: PET/CT scan can help staging patients with primary gastric lymphoma, and the maximum SUV has possibility to have prognostic value.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960998.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Czuczman MS, Vose J, Zinzani P, Reeder C, Buckstein R, Haioun C, Bouabdallah R, Polikoff J, Ervin-Haynes A, Witzig T: Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma: Results from an international study (NHL-003). J Clin Oncol; 2009 May 20;27(15_suppl):e19504

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma: Results from an international study (NHL-003).
  • : e19504 Background: Patients with diffuse large-B-cell lymphoma (DLBCL) who are not cured with R-CHOP or high-dose chemotherapy with autologous stem cell rescue have a dismal prognosis.
  • A recent phase II trial (NHL-002) of lenalidomide in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) demonstrated a 19% overall response rate (ORR) with a 7-month median duration of response (DR) in the subset of patients with DLBCL.
  • A supporting international phase II trial (NHL-003) of single-agent lenalidomide was initiated for patients with relapsed or refractory aggressive NHL that had received at least one prior treatment and had measurable disease.
  • METHODS: Patients received 25 mg oral lenalidomide once daily on days 1-21 of every 28-day cycle and continued therapy until disease progression or toxicity.
  • Median time from diagnosis was 2 years (0.4-18.6), patients had received a median of 3 prior treatment regimens (1-10) and 46 of the patients (45%) had received a prior stem cell transplant (DLBCL-stem cell).
  • CONCLUSIONS: This international study demonstrates that lenalidomide is active in heavily pre-treated patients with relapsed or refractory DLBCL and has manageable side effects.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960873.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Kim J, Kim E, Sohn B, Yoon D, Yoo C, Kim S, Lee D, Kim S, Lee J, Suh C: BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients. J Clin Oncol; 2009 May 20;27(15_suppl):7097

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients.
  • : 7097 Background: The objective of this study was to compare the efficacy and toxicity of two high-dose regimens for autologous stem cell transplantation (ASCT) in patients with non-Hodgkin's lymphoma (NHL): BEAM (BCNU, etoposide, cytarabine, and melphalan) and BuCyE (busulfan, cyclophosphamide, and etoposide).
  • METHODS: We analysed 65 NHL patients, who underwent high-dose chemotherapy with BEAM (N=43) or BuCyE (N=22), followed by ASCT, at the Asan Medical Center.
  • RESULTS: Median age was 46 years (range: 15-68), and baseline characteristics, such as gender, International Prognostic Index (IPI), age adjusted IPI, stage and status of disease at ASCT, and median number of infused CD 34+cells/kg were well balanced between groups.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961268.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Caces DD, Halaas J, Hamlin P, Noy A, Kewalramani T, Portlock CS, Zelenetz AD, O'Connor OA, Gerecitano JF: Therapeutic and palliative benefit from single-agent irinotecan in multiply treated and highly refractory cases of lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):e19554

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic and palliative benefit from single-agent irinotecan in multiply treated and highly refractory cases of lymphoma.
  • : e19554 Background: Multiple reports corroborate a role for irinotecan in the treatment of lymphoma.
  • This study describes the Memorial Sloan Kettering experience with single-agent irinotecan in the management of heavily pretreated and highly refractory cases of lymphoma.
  • METHODS: Adult patients with histologically diagnosed relapsed or refractory lymphoma treated with irinotecan between 1/2001 and 8/2008 were identified.
  • Treatment responses were evaluated based on the Revised Response Criteria for Malignant Lymphoma.
  • 4 patients had Hodgkin Lymphoma (HL) and 26 had Non-Hodgkin lymphoma (NHL): 17 DLBCL, 6 transformed follicular lymphoma, 1 mantle cell lymphoma, 1 T-cell lymphoma and 1 Burkitt's. 25 patients were evaluable for response.
  • 5 achieved an objective response (overall response rate 20%); 2 achieved complete remission (CR) and 3 partial remissions (PR).
  • 8 patients (32%) had stable disease and 12 (48%) progressed on treatment.
  • CONCLUSIONS: Irinotecan has utility even in multiply treated and highly refractory cases of lymphoma.
  • It can mitigate symptoms resulting from bulky disease and shows potential as a palliative treatment option.
  • Strategies that limit adverse reactions may enhance the agent's effectiveness in refractory lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961088.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Chen B, Mahmud F, Mangel J, Vujovic O, Rieder M, Zelcer S: Impaired endothelial function in Hodgkin lymphoma survivors receiving mediastinal radiation. J Clin Oncol; 2009 May 20;27(15_suppl):e19526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impaired endothelial function in Hodgkin lymphoma survivors receiving mediastinal radiation.
  • : e19526 Background: Mediastinal radiation (RT) is a cause of premature coronary artery disease (CAD) in Hodgkin lymphoma survivors (HLS).
  • Peripheral arterial tonometry (PAT) is a non-invasive technique that measures endothelial function (EF), as a surrogate marker of sub-clinical atherosclerosis.
  • The objective of our study was to evaluate EF in HLS and age-matched controls using PAT and to determine the association of mediastinal RT.
  • METHODS: Cross sectional evaluation of 26 HLS age 12-30 years and within a minimum of two years from the completion of therapy and matched controls.
  • RESULTS: HLS and controls were similar for baseline variables (mean age 23.2 ± 5 yrs; 23.4 ± 4.6 yrs, p=0.35).
  • HLS were on average 9.9 ± 3.9 yrs post treatment.
  • No differences in EF or cardiovascular risk factors were observed between HLS survivors and controls.
  • However impaired EF, as evidenced by lower PAT-HR (1.66 ± 0.18 vs. 2.08 ± 0.38, p<0.01) was seen in HLS (n=13) who received mantle/mediastinal RT (mean RT dose 2657 ± 971 cGy) compared to controls.
  • Mean cumulative anthracycline dose did not differ between HLS who did or did not receive RT (224.1 ± 65.4 vs. 253 ± 70.3 mg/m<sup>2</sup> p=0.18).
  • These differences were not explained by alterations in lipoproteins or hsCRP, however activity scores were significantly lower in HLS compared with young adult controls (2.01 ± 1.1 vs. 3.6 ± 1.2 hrs daily, p=0.02).
  • CONCLUSIONS: Impaired EF was observed in a small group of HLS who received mediastinal RT as compared to those who did not.
  • Cancer survivors at risk may benefit from early assessment of EF as a sub-clinical marker of CAD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960923.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement